---
title: "对 COVID-19 大流行的长期身心后遗症的系统回顾和荟萃分析：呼吁研究重点和行动"
date: 2022-12-05T15:03:26+08:00
updated: 2022-12-05T15:03:26+08:00
taxonomies:
  tags: []
extra:
  source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/
  hostname: www.ncbi.nlm.nih.gov
  author: 
  original_title: "A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action"
  original_lang: en
---

-   [Journal List](https://www.ncbi.nlm.nih.gov/pmc/journals/)
-   [Nature Public Health Emergency Collection](https://www.ncbi.nlm.nih.gov/pmc/?term=Nature%20Public%20Health%20Emergency%20Collection[filter])
-   PMC9168643

## Abstract

## 抽象的

The long-term physical and mental sequelae of COVID-19 are a growing public health concern, yet there is considerable uncertainty about their prevalence, persistence and predictors. We conducted a comprehensive, up-to-date meta-analysis of survivors’ health consequences and sequelae for COVID-19. PubMed, Embase and the Cochrane Library were searched through Sep 30th, 2021. Observational studies that reported the prevalence of sequelae of COVID-19 were included. Two reviewers independently undertook the data extraction and quality assessment. Of the 36,625 records identified, a total of 151 studies were included involving 1,285,407 participants from thirty-two countries. At least one sequelae symptom occurred in 50.1% (95% CI 45.4-54.8) of COVID-19 survivors for up to 12 months after infection. The most common investigation findings included abnormalities on lung CT (56.9%, 95% CI 46.2–67.3) and abnormal pulmonary function tests (45.6%, 95% CI 36.3–55.0), followed by generalized symptoms, such as fatigue (28.7%, 95% CI 21.0–37.0), psychiatric symptoms (19.7%, 95% CI 16.1–23.6) mainly depression (18.3%, 95% CI 13.3–23.8) and PTSD (17.9%, 95% CI 11.6–25.3), and neurological symptoms (18.7%, 95% CI 16.2–21.4), such as cognitive deficits (19.7%, 95% CI 8.8–33.4) and memory impairment (17.5%, 95% CI 8.1–29.6). Subgroup analysis showed that participants with a higher risk of long-term sequelae were older, mostly male, living in a high-income country, with more severe status at acute infection. Individuals with severe infection suffered more from PTSD, sleep disturbance, cognitive deficits, concentration impairment, and gustatory dysfunction. Survivors with mild infection had high burden of anxiety and memory impairment after recovery. Our findings suggest that after recovery from acute COVID-19, half of survivors still have a high burden of either physical or mental sequelae up to at least 12 months. It is important to provide urgent and appropriate prevention and intervention management to preclude persistent or emerging long-term sequelae and to promote the physical and psychiatric wellbeing of COVID-19 survivors.

COVID-19 的长期身心后遗症是一个日益受到关注的公共卫生问题，但其流行率、持续性和预测因素存在相当大的不确定性。 我们对 COVID-19 幸存者的健康后果和后遗症进行了全面、最新的荟萃分析。 检索了截至 2021 年 9 月 30 日的 PubMed、Embase 和 Cochrane 图书馆。包括报告 COVID-19 后遗症流行率的观察性研究。 两名评价者独立进行数据提取和质量评估。 在确定的 36,625 份记录中，共有 151 项研究被纳入，涉及来自 32 个国家的 1,285,407 名参与者。 在感染后长达 12 个月的时间里，50.1%（95% CI 45.4-54.8）的 COVID-19 幸存者至少出现一种后遗症症状。 最常见的调查结果包括肺部 CT 异常（56.9%，95% CI 46.2-67.3）和肺功能检查异常（45.6%，95% CI 36.3-55.0），其次是全身症状，如疲劳（28.7%， 95% CI 21.0–37.0）、精神症状（19.7%，95% CI 16.1–23.6）主要是抑郁症（18.3%，95% CI 13.3–23.8）和 PTSD（17.9%，95% CI 11.6–25.3），以及神经症状症状（18.7%，95% CI 16.2-21.4），例如认知缺陷（19.7%，95% CI 8.8-33.4）和记忆障碍（17.5%，95% CI 8.1-29.6）。 亚组分析显示，长期后遗症风险较高的参与者年龄较大，多为男性，生活在高收入国家，急性感染时病情较重。 严重感染的个体更容易出现创伤后应激障碍、睡眠障碍、认知缺陷、注意力不集中和味觉功能障碍。 轻度感染的幸存者在康复后有很高的焦虑负担和记忆障碍。 我们的研究结果表明，在从急性 COVID-19 康复后，一半的幸存者仍然有至少 12 个月的身体或精神后遗症的高负担。 重要的是提供紧急和适当的预防和干预管理，以排除持续或新出现的长期后遗症，并促进 COVID-19 幸存者的身心健康。

**Subject terms:** Depression, Prognostic markers

## Introduction

## 介绍

Severe acute respiratory syndrome-2 (SARS-COV-2) is the novel coronavirus causing the coronavirus disease 2019 (COVID-19) pandemic \[[1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR1)\]. By April 2022, COVID-19 had caused 488 million confirmed cases and 6.1 million deaths globally. The clinical features, pathogenesis, transmission, diagnosis, and complications of patients with COVID-19 during the acute phase have been comprehensively described \[[2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR2), [3](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR3)\], however, survivors of acute COVID-19 still risk long-term sequelae affecting multiple body organs systems, including the brain and nervous system. Understanding the long-term health burden of COVID-19 is essential to allow timely identification and treatment of affected patients and appropriate allocation of healthcare resources.

严重急性呼吸综合征 2 (SARS-COV-2) 是引起 2019 年冠状病毒病 (COVID-19) 大流行的新型冠状病毒 \[ [1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR1) \]。 到 2022 年 4 月，COVID-19 已在全球造成 4.88 亿例确诊病例和 610 万例死亡。 COVID-19 患者急性期的临床特征、发病机制、传播、诊断和并发症已得到全面描述 \[ [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR2) , [3](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR3) \]，但是，急性 COVID-19 的幸存者仍面临影响多个身体器官的长期后遗症的风险系统，包括大脑和神经系统。 了解 COVID-19 的长期健康负担对于及时识别和治疗受影响的患者以及适当分配医疗资源至关重要。

Investigations of longitudinal epidemiology and follow-up have uncovered a large variety of long-term sequelae in survivors of the COVID-19 pandemic \[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4)–[8](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR8)\]. Studies have reported that as many as 80% of patients discharged after hospitalization had at least one symptom persisting 2–6 months after disease onset, including fatigue, muscle weakness, and sleep difficulties, affecting body systems ranging from cardiopulmonary to psychiatric and neurological \[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4), [6](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR6), [9](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR9), [10](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR10)\]. Additionally, more than half of the patients had abnormal lung computed tomography (CT) images and impaired pulmonary function \[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4), [11](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR11), [12](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR12)\]. In the absence of effective treatment, the persistence of these sequelae may cause chronic or even permanent suffering in COVID-19 survivors, negatively affecting their quality of life and delaying returning to work for those who were at working age \[[13](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR13), [14](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR14)\].

\-19 大流行幸存者存在多种多样的长期后遗症 \[ [纵向流行病学调查和随访发现， COVID](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4) 4-8 [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR8) 。 研究报告说，多达 80% 的住院出院患者在发病后 2-6 个月至少有一种症状持续存在，包括疲劳、肌肉无力和睡眠困难，影响从心肺到精神和神经系统的身体系统 \[ [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4) \] , [6](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR6) , [9](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR9) , [10](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR10) \]。 肺功能 [4、11、12](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4) 此外，超过一半的患者肺部计算机断层扫描 (CT) 图像异常， [受损](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR11) \[ [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR12) 。 幸存者带来慢性甚至永久性的痛苦，对他们的生活质量产生负面影响，并延迟那些处于工作年龄的人重返工作岗位 \[ [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR13) 13、14 [在没有有效治疗的情况下，这些后遗症的持续存在可能会给 COVID- 19](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR14) 。

Due to the novel nature of the COVID-19 pandemic, evidence of long-term sequelae is still emerging. Considering that SARS-COV-2 is in the same beta-coronavirus clade as SARS-CoV-1 and MERS-CoV, it is possible that some of the chronic problems encountered by survivors of SARS and MERS may also apply to COVID-19 survivors. Previous studies show that SARS survivors were identified to have markedly lower health status and exercise capacity at 1 year after acute illness, and 24% still experienced impaired lung diffusing capacity by that time \[[15](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR15)\]. A 15-year follow-up study of SARS survivors indicated a 2-year recovery time after rehabilitation for pulmonary interstitial damage and functional decline to resolve \[[16](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR16)\]. Chronic physical illness has been shown to increase the risk of developing psychiatric disorders, therefore long-term sequelae in any body system may further impact on survivors’ mental health. One study showed high levels of psychiatric distress among MERS survivors even 12 months after acute infection, with 42% of patients experiencing signs of post-traumatic stress disorder (PTSD) and 27% experiencing depression \[[17](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR17)\]. Based on these findings, we predict that the sequelae of the COVID-19 pandemic are likely to remain a significant global challenge in the months and years ahead.

由于 COVID-19 大流行的新颖性，长期后遗症的证据仍在出现。 考虑到 SARS-COV-2 与 SARS-CoV-1 和 MERS-CoV 属于同一 β-冠状病毒进化枝，SARS 和 MERS 幸存者遇到的一些慢性问题可能也适用于 COVID-19 幸存者. 先前的研究表明，SARS 幸存者在急性病后 1 年的健康状况和运动能力明显较低，到那时仍有 24% 的人肺弥散能力受损 \[ [15](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR15) \]。 对 SARS 幸存者进行为期 15 年的随访研究表明，肺间质损伤和功能衰退的康复需要 2 年的恢复时间才能解决 \[ [16](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR16) \]。 慢性身体疾病已被证明会增加患精神疾病的风险，因此任何身体系统的长期后遗症都可能进一步影响幸存者的心理健康。 一项研究表明，即使在急性感染 12 个月后，MERS 幸存者仍存在高水平的精神痛苦，42% 的患者出现创伤后应激障碍 (PTSD) 迹象，27% 的患者出现抑郁症 \[ [17](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR17) \]。 基于这些发现，我们预测 COVID-19 大流行的后遗症可能在未来数月和数年内仍然是一个重大的全球挑战。

Most studies of the sequelae of COVID-19 to date are heterogeneous. Accordingly, there is uncertainty about the relative prevalence of different symptoms and radiographic findings, their longevity and the factors that predict them. Although a recent meta-analysis estimated the prevalence of long-term effects of COVID-19, it included only 15 studies with a follow-up duration less than 4 months from infection and did not identify influential factors correlated with health sequelae \[[18](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR18)\]. A better understanding of the convalescent phase among COVID-19 survivors would help direct clinical care and tailor public health strategies in the post-epidemic era. In this meta-analysis, we aimed to (1) quantitatively estimate the pooled prevalence of long-term sequelae overall, as well as those of specific organ systems, in particular, neuropsychiatric symptoms; (2) to evaluate whether patient characteristics and clinical factors have different impacts on COVID-19 long-term sequelae; and (3) to explore the biomarkers and mechanism of such sequelae. We systematically review the current evidence of the long-term health consequences of COVID-19 infection which, to our knowledge, is the largest and most wide-ranging analysis of its kind to date. We identify important emerging trends that can inform further research and healthcare provision targeted at this urgent, expanding health needs.

迄今为止，大多数关于 COVID-19 后遗症的研究都是异质性的。 因此，不同症状和影像学发现的相对流行程度、它们的寿命以及预测它们的因素存在不确定性。 尽管最近的一项荟萃分析估计了 COVID-19 长期影响的普遍性，但它仅包括 15 项研究，随访时间从感染开始不到 4 个月，并且没有确定与健康后遗症相关的影响因素 \[ [18](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR18) \]。 更好地了解 COVID-19 幸存者的康复期将有助于在后流行病时代指导临床护理和制定公共卫生战略。 在这项荟萃分析中，我们的目的是 (1) 定量估计总体长期后遗症的合并患病率，以及特定器官系统的合并患病率，特别是神经精神症状； (2) 评估患者特征和临床因素是否对 COVID-19 远期后遗症有不同影响； (3) 探索此类后遗症的生物标志物和机制。 我们系统地审查了有关 COVID-19 感染的长期健康后果的当前证据，据我们所知，这是迄今为止规模最大、范围最广的此类分析。 我们确定了重要的新兴趋势，这些趋势可以为针对这一紧迫且不断扩大的健康需求的进一步研究和医疗保健提供提供信息。

## Methods

## 方法

We conducted this systematic review and meta-analysis in accordance with the principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, Supplementary Table [S1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)) \[[19](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR19)\]. We registered the protocol of this study on the PROSPERO platform (Registration Number: CRD42021228197).

的原则进行了这项系统评价和荟萃分析 [我们根据系统评价和荟萃分析的首选报告项目（PRISMA，补充表S1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) ）\[ [19](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR19) \] 。 我们在 PROSPERO 平台上注册了本研究的协议（注册号：CRD42021228197）。

### Data sources and searches

### 数据源和搜索

We searched and updated the PubMed, Embase, and Cochrane Library databases for studies published in English up to Sep 30th, 2021. The search strategy was developed by the senior authors (Supplementary Appendix [1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)). Search terms included coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2, COVID-19, SARS-COV-2, 2019-nCoV, and novel coronavirus in conjunction with recovery, discharge, survival, and sequelae. The reference lists of original articles and reviews in the field were also manually examined to identify additional studies. References were managed with EndNote software version X9.3. Given that this field is developing rapidly, we also searched the preprint server medRxiv for studies published before Sep 30, 2021, with the terms “COVID-19” and “sequelae” in the title or abstract.

我们搜索并更新了 PubMed、Embase 和 Cochrane 图书馆数据库，以查找截至 2021 年 9 月 30 日以英文发表的研究。搜索策略由资深作者制定（补充附录 [1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) ）。 搜索词包括冠状病毒病 2019、严重急性呼吸系统综合症冠状病毒 2、COVID-19、SARS-COV-2、2019-nCoV 和新型冠状病毒，以及恢复、出院、存活和后遗症。 还手动检查了该领域原始文章和评论的参考列表，以确定其他研究。 使用 EndNote 软件版本 X9.3 管理参考文献。 鉴于该领域发展迅速，我们还在预印本服务器 medRxiv 中搜索了 2021 年 9 月 30 日之前发表的标题或摘要中包含术语“COVID-19”和“后遗症”的研究。

#### Study selection

#### 研究选择

Articles were included if they met the following criteria: (1) original research; (2) follow-up studies including patients recovering from COVID-19; (3) reported at least one symptom, relevant laboratory or examination result (such as lung imaging, lung function tests or blood tests) of post-acute COVID-19 or (4) provided raw data that allowed the calculation of the estimates. We used 4 weeks after initial infection as a cut-off for post/long-COVID syndrome \[[20](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR20)\]. In our study, 10 studies \[[21](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR21)–[30](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR30)\] with follow up duration of 2–4 weeks from discharge from hospitals were included, because of their average duration of more than 4 weeks after onset of infection, considering an average period in hospital of 22 days from illness onset \[[31](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR31)\]. The exclusion criteria were as follows: (1) the study was a review article or an abstract; (2) the study did not report the persistent symptoms of COVID-19 during the recovery stage; (3) the study was a case report based on a single patient.

符合以下标准的文章被收录：（1）原创性研究； (2) 后续研究包括从 COVID-19 中康复的患者； (3) 报告至少一种急性后 COVID-19 症状、相关实验室或检查结果（如肺部成像、肺功能测试或血液测试）或 (4) 提供允许计算估计值的原始数据。 我们使用初次感染后 4 周作为后/长 COVID 综合征的分界点 \[ [20](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR20) \]。 项研究 \[ [21-30](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR21) \] ， [在我们的研究中，纳入了10](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR30) 随访时间为出院后 2-4 周，因为考虑到平均住院时间为 22 周，它们在感染发作后的平均持续时间超过 4 周发病天数 \[ [31](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR31) \]。 排除标准如下：（1）该研究为综述文章或摘要； (2) 该研究未报告 COVID-19 在恢复阶段的持续症状； (3) 该研究是基于单个患者的病例报告。

The full texts of the identified articles were reviewed by two authors (NZ and YMZ). Disagreements on the inclusion of articles were resolved by consensus or involvement of a senior expert (YPB).

已识别文章的全文由两位作者（NZ 和 YMZ）审阅。 通过共识或高级专家 (YPB) 的参与解决了关于文章纳入的分歧。

### Data extraction and quality assessment

### 数据提取和质量评估

Data were extracted using Excel software with respect to study information (author, geographical location, publication year, sample size, severity of participants during acute infection and follow-up duration), population characteristics (mean age, male proportion), and reported health sequelae of COVID-19. Objective respiratory findings included CT abnormalities and abnormal pulmonary function tests. Subjective respiratory symptoms included dyspnea, cough, chest distress, chest pain, sputum, sore throat, and pharyngeal symptoms. Generalized symptoms included fatigue, sweat, joint pain, fever, myalgia, functional decline, moving difficulty, body aches, weight loss, and chills. Psychiatric sequelae included anxiety, mood disorder, depression, post-traumatic stress disorder (PTSD), sleep disturbance, stress, obsessive thinking, irritability, suicidality, behavior changes, hallucinations and neurological sequelae including cognitive deficit, headache, olfactory dysfunction, gustatory dysfunction, dementia, memory impairment, concentration impairment, visual disturbances, parasthesia, confusion, hearing loss, tremor, verbal problems, and dizziness. Objective Cardiovascular findings as well as subjective cardiovascular symptoms of palpitation, sinus bradycardia, hypertension, arrythmia or palpitations and angina pectoris. Digestive symptoms included gastrointestinal symptoms, nausea, abdominal pain, swallowing problems and diarrhea. Hair loss, pruritus and pash skin conditions were also reported. Nucleic re-positive and hospital readmission rates were included. Symptoms reported by more than 5 studies are shown in Fig. [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig2/), while those reported by fewer than five studies are listed in the [supplementary file](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1). Four investigators (NZ, YMZ, CL, and QDL) extracted data independently.

使用 Excel 软件提取有关研究信息（作者、地理位置、出版年份、样本量、急性感染期间参与者的严重程度和随访持续时间）、人群特征（平均年龄、男性比例）和报告的健康后遗症的数据COVID-19。 客观呼吸检查结果包括 CT 异常和肺功能检查异常。 主观呼吸道症状包括呼吸困难、咳嗽、胸闷、胸痛、咳痰、咽痛和咽部症状。 全身症状包括疲劳、出汗、关节痛、发烧、肌痛、功能下降、移动困难、身体疼痛、体重减轻和发冷。 精神后遗症包括焦虑、情绪障碍、抑郁、创伤后应激障碍（PTSD）、睡眠障碍、压力、强迫性思维、易怒、自杀、行为改变、幻觉和神经系统后遗症，包括认知缺陷、头痛、嗅觉障碍、味觉障碍、痴呆、记忆障碍、注意力不集中、视觉障碍、感觉异常、意识模糊、听力丧失、震颤、言语问题和头晕。 目的心血管检查结果以及心悸、窦性心动过缓、高血压、心律失常或心悸和心绞痛等主观心血管症状。 消化系统症状包括胃肠道症状、恶心、腹痛、吞咽困难和腹泻。 脱发、瘙痒和皮疹也有报道。 包括核酸再阳性率和再入院率。 超过 5 项研究报告的症状如图 1 所示。 [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig2/) ，而少于五项研究报告的则在 [补充文件](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) 中列出。 四名研究者（NZ、YMZ、CL 和 QDL）独立提取数据。

[](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig2/)

[![包含图片、插图等的外部文件。 
对象名称是 41380_2022_1614_Fig2_HTML.jpg](41380_2022_1614_Fig2_HTML.jpg "点击图片放大")](https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=9168643_41380_2022_1614_Fig2_HTML.jpg)

**The pooled prevalence of sequelae by organ system and specific symptoms of COVID-19.**

(Symptoms reported by more than five studies are shown in Fig. 2). In total, 50.1% of patients were estimated to have at least one symptom at follow-up, and the objectively examined respiratory system was most commonly affected, followed by generalized symptoms, subjective respiratory symptoms, psychiatric symptoms, and the neurological system. The prevalence of patients re-testing positive by SARS-COV-2SARS-COV-2 nucleic acid PCR and readmission to the hospital were estimated to be 9.9% and 13.6%, respectively.

（超过五项研究报告的症状如图 2 所示）。 总共估计有 50.1% 的患者在随访时至少有一种症状，客观检查的呼吸系统最常受累，其次是全身症状、主观呼吸系统症状、精神症状和神经系统。 通过 SARS-COV-2SARS-COV-2 核酸 PCR 重新检测呈阳性和再次入院的患者的患病率估计分别为 9.9% 和 13.6%。

The risk of bias of the included studies was assessed by the criteria of the Newcastle–Ottawa quality assessment scale. Based on the NOS criteria, we assigned a maximum of four stars for selection bias, two stars for comparability evaluation, and three stars for exposure and outcome assessment. Studies with fewer than five stars were considered low quality; five to seven stars, moderate quality; and more than seven stars, high quality. Four investigators (NZ, YMZ, CL, and QDL) independently appraised each item of the scale. Disagreements were settled by joint review with an experienced methodologist (YPB).

纳入研究的偏倚风险根据纽卡斯尔-渥太华质量评估量表的标准进行评估。 根据 NOS 标准，我们为选择偏差分配了最多四颗星，为可比性评估分配了两颗星，为暴露和结果评估分配了三颗星。 少于五颗星的研究被认为是低质量的； 五到七颗星，质量中等； 而且七颗星以上，质量上乘。 四名调查员（NZ、YMZ、CL 和 QDL）独立评估了量表的每个项目。 通过与经验丰富的方法学家 (YPB) 的联合审查解决分歧。

### Data synthesis and analysis

### 数据综合与分析

Meta-analysis was performed to estimate the pooled prevalence of each sequelae among COVID-19 survivors after discharge from the hospital. The main affected systems included the respiratory, generalized, psychiatric, neurological, cardiovascular, dermatological, and digestive systems. The prevalence of any symptom within a specific organ system was estimated by pooling the most common symptoms related to that system, reported in one study. The I<sup>2</sup> index was calculated to assess the between-study heterogeneity, and the Cochrane _Q_\-test was used to determine statistical significance. An I<sup>2</sup> value >50% or a chi-square _p_ value <0.05 was considered substantial heterogeneity. Pooled rates with 95% confidence intervals (95% CIs) were calculated using the random-effect model if heterogeneity existed; otherwise, the fixed-effect model was used.

进行了荟萃分析，以估计出院后 COVID-19 幸存者中每种后遗症的合并患病率。 主要受影响的系统包括呼吸系统、全身系统、精神系统、神经系统、心血管系统、皮肤病系统和消化系统。 一项研究报告称，通过汇集与该系统相关的最常见症状来估计特定器官系统内任何症状的流行程度。 计算I <sup><span>2 </span></sup> 指数以评估研究间的异质性，并使用 Cochrane _Q_ 检验确定统计显着性。 I <sup><span>2 </span></sup> 值 >50% 或卡方 _p_ 值 <0.05 被认为具有显着异质性。 如果存在异质性，则使用随机效应模型计算具有 95% 置信区间 (95% CI) 的汇总率； 否则，使用固定效应模型。

Subgroup analyses and meta-regression on the estimated prevalence of any symptom in each system were performed by stratification with mean age of study participants, the male proportion of the studies, the follow up duration, the severity of acute infection of COVID-19 (community patients, mild or moderate hospitalized patients and hospitalized patients who were admitted to intensive care) and whether study was conducted in high-income country or middle- or low-income country by World Bank income groups \[[32](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR32)\]. Funnel plots and Egger’s test were used to assess the presence of any publication biases. All analyses were performed with R Software (version 4.0.3).

通过对研究参与者的平均年龄、研究中的男性比例、随访时间、COVID-19 急性感染的严重程度（社区患者、轻度或中度住院患者和接受重症监护的住院患者）以及世界银行收入组是否在高收入国家或中低收入国家进行了研究 \[ [32](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR32) \]。 漏斗图和 Egger 检验用于评估是否存在任何发表偏倚。 所有分析均使用 R 软件（4.0.3 版）进行。

## Results

## 结果

### Characteristics of included studies

### 纳入研究的特征

The search strategy yielded a total of 36,625 articles, with 19,272 from EMBASE, 14,622 from PubMed, 2158 from Cochrane Library and 573 from medRxiv. After the removal of duplicates, the titles and abstracts of 28,206 records were screened. A total of 349 were assessed for eligibility by full-text review, and 198 did not meet the inclusion criteria and were therefore excluded. Finally, 151 eligible studies involving 1,285,407 participants were included (Fig. [1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig1/)).

搜索策略总共产生了 36,625 篇文章，其中 19,272 篇来自 EMBASE，14,622 篇来自 PubMed，2158 篇来自 Cochrane Library，573 篇来自 medRxiv。 去重后筛选了28206条记录的标题和摘要。 共有 349 人通过全文审查进行了资格评估，198 人不符合纳入标准，因此被排除在外。 最后，纳入了 151 项符合条件的研究，涉及 1,285,407 名参与者（图 [1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig1/) ）。

[](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig1/)

[![包含图片、插图等的外部文件。 
对象名称是 41380_2022_1614_Fig1_HTML.jpg](41380_2022_1614_Fig1_HTML.jpg "点击图片放大")](https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=9168643_41380_2022_1614_Fig1_HTML.jpg)

Flow chart of study selection.

研究选择流程图。

The characteristics of the included studies and their corresponding quality scores are reported in Supplementary Table [S2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1). These studies covered 32 countries (35 in China, 23 in the USA, 21 in Italy, 12 in Spain, 9 in the UK, 4 in France, 4 in Germany, 4 in India, 3 in Norway, 3 in Belgium, 3 in the Netherlands, 3 in Switzerland, 3 in Sweden, 2 in Austria, 2 in Bangladesh, 2 in Iran, 2 in Mexico, one each for Australia, Brazil, Canada, Croatia, Egypt, Finland, Ireland, Japan, Nigeria, South Korea, Thailand, The Republic of North Macedonia, Russia, Turkey, United Arab Emirates and a multinational study). Most studies were prospective (_n_ = 110), 21 were cross-sectional and 20 were retrospective. Overall, across the 151 studies, the long-term effects of COVID-19 on seven organ systems and 102 specific symptoms were included in this meta-analysis. Findings related to the respiratory system (90, 59.6%) were most commonly reported, including lung CT abnormalities (_n_ = 23), pulmonary function tests (_n_ = 15) or subjective respiratory symptoms (_n_ = 75). This was followed by studies reporting generalized symptoms (_n_ = 76, 50.3%), neurological effects (_n_ = 68, 45.0%), psychiatric symptoms (_n_ = 59, 39.1%), digestive symptoms (_n_ = 40, 26.5%), cardiovascular symptoms (_n_ = 30, 19.9%) and dermatological symptoms (_n_ = 18, 11.9%). Fourteen (9.3%) studies reported the prevalence of cases who retested positive for COVID-19. Seventeen studies identified patients with varying severity of infection, involving 1026 community patients, 3114 mild or moderate hospitalized cases and 605 severe hospitalized cases. The follow-up duration was up to 12 months after discharge from the hospital.

中报告了纳入研究的特征及其相应的质量评分 [补充表S2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) 。 这些研究覆盖了 32 个国家（中国 35 个、美国 23 个、意大利 21 个、西班牙 12 个、英国 9 个、法国 4 个、德国 4 个、印度 4 个、挪威 3 个、比利时 3 个、英国 3 个）。荷兰、瑞士3个、瑞典3个、奥地利2个、孟加拉国2个、伊朗2个、墨西哥2个、澳大利亚、巴西、加拿大、克罗地亚、埃及、芬兰、爱尔兰、日本、尼日利亚、韩国各1个、泰国、北马其顿共和国、俄罗斯、土耳其、阿拉伯联合酋长国和一项多国研究）。 大多数研究是前瞻性的（ _n_ \= 110），21 项是横断面研究，20 项是回顾性研究。 总体而言，在 151 项研究中，COVID-19 对七个器官系统和 102 种特定症状的长期影响被纳入该荟萃分析。 与呼吸系统相关的发现 (90, 59.6%) 最常报告，包括肺部 CT 异常 ( _n_ \= 23)、肺功能检查 ( _n_ \= 15) 或主观呼吸道症状 ( _n_ \= 75)。 其次是报告全身症状（ _n_ \= 76, 50.3%）、神经系统影响（ _n_ \= 68, 45.0%）、精神症状（ _n_ \= 59, 39.1%）、消化系统症状（ _n_ \= 40, 26.5%）、心血管症状 ( _n_ \= 30, 19.9%) 和皮肤病症状 ( _n_ \= 18, 11.9%)。 十四项 (9.3%) 研究报告了 COVID-19 重新检测呈阳性的病例的流行率。 17 项研究确定了感染严重程度不同的患者，涉及 1026 名社区患者、3114 名轻度或中度住院病例和 605 名重度住院病例。 出院后随访时间长达12个月。

### Long-term sequelae by organ systems and specific symptoms among recovered survivors

### 器官系统的长期后遗症和康复幸存者的特定症状

#### The pooled prevalence of system sequelae

#### 系统后遗症的合并患病率

Figure [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig2/) summarizes the pooled estimates of overall and specific symptoms in multiple organ systems in COVID-19 survivors after recovery. A total of 50.1% (95% CI 45.4–54.8, from thirty-seven studies, 659,454 participants) of participants were estimated to have at least one self-reported symptom up to the 12-month follow-up.

图 [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig2/) 总结了 COVID-19 幸存者康复后多器官系统的总体和特定症状的汇总估计。 据估计，在 12 个月的随访中，共有 50.1%（95% CI 45.4–54.8，来自 37 项研究，659,454 名参与者）的参与者至少有一种自我报告的症状。

Of all organ systems, the respiratory system was most commonly affected with an estimated 55.6% (95% CI 46.8–64.2) of patients experiencing abnormalities in any objective examination results based on 32 studies (6292 participants), including either abnormalities on lung CT (56.9%, 95% CI 46.2–67.3) or abnormal pulmonary function testing (45.6%, 95% CI 36.3–55.0). Self-reported respiratory symptoms from 75 studies (550,319 participants) were estimated to be present in 25.7% of patients (95% CI 21.4–30.2). Generalized symptoms were also prevalent (28.7%, 95% CI 21.0–37.0) in 76 studies (502,540 participants), including 28.3% (95% CI 23.9–32.9) of survivors reporting fatigue. Psychiatric symptoms were frequently reported, with a pooled prevalence estimated to be 19.7% (95% CI 16.1–23.6) by pooling 59 studies (737,901 participants). Neurological symptoms still affected a considerable proportion of patients (18.7%, 95% CI 16.2–21.4) based on 68 studies (738,430 participants). Cardiovascular symptoms, digestive symptoms and dermatological symptoms were estimated to affect 14.8% (95% CI 10.0–20.3), 9.6% (95% CI 6.7–13.0) and 10.2% (95% CI 6.6–14.6) of survivors up to 12 months post-discharge from the hospital, respectively. The prevalence of patients re-testing positive by SARS-COV-2 nucleic acid PCR after a period of negative testing was estimated to be 9.9% (95% CI 6.1–14.4), although whether this represents true reinfection is unclear. The prevalence of readmission to the hospital was estimated to be 13.6% (95% CI 7.3–21.5). Other specific sequelae in COVID-19 survivors are shown in Fig. [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig2/) and Supplementary Figs [S1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)–[S13](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1).

在所有器官系统中，呼吸系统最常受到影响，估计有 55.6% (95% CI 46.8–64.2) 的患者在基于 32 项研究（6292 名受试者）的任何客观检查结果中出现异常，包括肺部 CT 异常（ 56.9%, 95% CI 46.2–67.3) 或肺功能检测异常 (45.6%, 95% CI 36.3–55.0)。 来自 75 项研究（550,319 名参与者）的自我报告的呼吸道症状估计出现在 25.7% 的患者中（95% CI 21.4–30.2）。 在 76 项研究（502,540 名参与者）中，全身症状也很普遍（28.7%，95% CI 21.0-37.0），其中 28.3%（95% CI 23.9-32.9）的幸存者报告疲劳。 经常报告精神症状，通过汇总 59 项研究（737,901 名参与者），汇总患病率估计为 19.7%（95% CI 16.1–23.6）。 根据 68 项研究（738,430 名参与者），神经系统症状仍然影响相当大比例的患者（18.7%，95% CI 16.2–21.4）。 据估计，心血管症状、消化系统症状和皮肤病症状会影响 14.8% (95% CI 10.0–20.3)、9.6% (95% CI 6.7–13.0) 和 10.2% (95% CI 6.6–14.6) 长达 12 个月的幸存者分别出院后。 经过一段时间的阴性检测后，通过 SARS-COV-2 核酸 PCR 重新检测呈阳性的患者的患病率估计为 9.9%（95% CI 6.1-14.4），尽管这是否代表真正的再感染尚不清楚。 再入院率估计为 13.6% (95% CI 7.3–21.5)。 COVID-19 幸存者的其他特定后遗症如图 1 所示。 [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig2/) 和补充图 [S1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) – [S13](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) 。

#### Effect of clinical characteristics and demographic factors on system symptoms

#### 临床特征和人口统计学因素对系统症状的影响

We conducted subgroup analyses for follow-up duration in longitudinal studies, the severity of acute infection, mean age, proportion of male participants, and income level (Fig. [3](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig3/), and Supplementary Figs [S14](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)–[S20](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)). We found that longer follow-up duration was associated with lower reported prevalence of sequelae (Fig. [3A](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig3/)). The temporal trend in symptom sequelae showed that the proportion of patients with at least one sequelae symptom decreased from 56.0% (at 1–3 months) to 48.7% (at 3–6 months) and 37.8% (at 6–12 months). The prevalence of sequelae in each specific organ system increased according to the severity of the acute infection, from the lowest prevalence in community cases to the highest prevalence among those who were hospitalized as severely or critically ill patients (Fig. [3B](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig3/)). Subgroup analyses showed that elderly and male participants were at increased risk of reporting any symptoms (Fig. [3C, D](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig3/)). For the specific organ systems, elderly participants were at significantly increased risk of abnormal pulmonary function tests, whereas younger and male participants reported a significant higher prevalence of cardiovascular symptoms. In addition, COVID-19 survivors who lived in a high-income country had an increased risk of respiratory symptoms, generalized symptoms, and neurological symptoms (Fig. [3E](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig3/)).

我们对纵向研究的随访时间、急性感染的严重程度、平均年龄、男性参与者的比例和收入水平进行了亚组分析（图 [3](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig3/) 和补充图 [S14](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) \- [S20](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) ）。 我们发现，较长的随访时间与报告的后遗症患病率较低有关（图 [3A](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig3/) ）。 症状后遗症的时间趋势表明，至少有一种后遗症症状的患者比例从 56.0%（1-3 个月）下降到 48.7%（3-6 个月）和 37.8%（6-12 个月）。 每个特定器官系统的后遗症患病率根据急性感染的严重程度而增加，从社区病例中的最低患病率到重症或危重症住院患者中的最高患病率（图 [3B](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig3/) ）。 亚组分析显示，老年和男性参与者报告任何症状的风险增加（图 [3C、D](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig3/) ）。 对于特定器官系统，老年参与者肺功能检查异常的风险显着增加，而年轻和男性参与者报告心血管症状的患病率显着增加。 此外，生活在高收入国家的 COVID-19 幸存者出现呼吸道症状、全身症状和神经系统症状的风险增加（图 1）。 [3E](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig3/) ）。

[](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig3/)

[![包含图片、插图等的外部文件。 
对象名称是 41380_2022_1614_Fig3_HTML.jpg](41380_2022_1614_Fig3_HTML.jpg "点击图片放大")](https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=9168643_41380_2022_1614_Fig3_HTML.jpg)

**Subgroup analysis of sequelae of COVID-19 by mean age, sex proportion, region of studies, severity of disease and follow-up duration.**

NS No. of studies, NP No. of participants. COVID-19 survivors of senior age, male sex, living in a high-income country, had a more severe health statuses at acute infection and within 6 months since recovery appeared to have higher prevalence of long-term sequelae than their contrast groups; **A** Subgroup analysis among different follow-up duration; **B** Subgroup analysis among asymptomatic participants in the community, mild/moderate patients and severe patients in hospital; **C** Subgroup analysis by mean age of participants; **D** Subgroup analysis by sex proportion of studies; **E** Subgroup analysis between high-income country and middle or low-income country.

NS 研究数量，NP 参与者数量。 生活在高收入国家的高龄男性 COVID-19 幸存者在急性感染时的健康状况更为严重，康复后 6 个月内的长期后遗症患病率似乎高于对照组； **；** 不同随访时间的亚组分析 **B** 社区无症状参与者、轻/中度患者和住院重症患者的亚组分析； **C** 按参与者平均年龄进行亚组分析； **D** 按研究的性别比例进行亚组分析； **E** 高收入国家与中等或低收入国家之间的亚组分析。

### Long-term neuropsychiatric symptoms among recovered survivors

### 康复幸存者的长期神经精神症状

#### The pooled prevalence of neuropsychiatric symptoms

#### 神经精神症状的汇总患病率

Psychiatric problems and neurological symptoms were most reported after respiratory and generalized symptoms. We specifically estimated the pooled prevalence of each sequela of neuropsychiatric symptoms (Fig. [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig2/)). Psychiatric symptoms among recovered survivors were reported as, 18.3% (95% CI 13.3–23.8) for depression, 17.9% (95% CI 11.6–25.3) for PTSD, 16.2% (95% CI 12.0–20.8) for anxiety and 13.5% (95% CI 8.7–19.2) for sleep disturbance. Reports of mild/moderate anxiety (41.2%, 95% CI 7.5–80.6) were significantly more common than severe/very severe anxiety (6.0%, 95% CI 1.7–12.6%) (_P_ = 0.04). For neurological symptoms, cognitive deficits (19.7%, 95% CI 8.8–33.4), memory impairment (17.5%, 95% CI 8.6–29.6) and loss of taste or smell (15.7%, 95% CI 6.6–27.8) were most commonly reported.

在呼吸系统和全身症状之后，精神问题和神经系统症状的报告最多。 我们专门估计了每种神经精神症状后遗症的合并患病率（图 [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig2/) ）。 据报道，康复幸存者的精神症状为抑郁症 18.3% (95% CI 13.3-23.8)，创伤后应激障碍 17.9% (95% CI 11.6-25.3)，焦虑症 16.2% (95% CI 12.0-20.8) 和 13.5% (95% CI 8.7–19.2) 睡眠障碍。 轻度/中度焦虑 (41.2%, 95% CI 7.5–80.6) 的报告明显多于重度/极重度焦虑 (6.0%, 95% CI 1.7–12.6%) ( _P_ \= 0.04)。 对于神经系统症状，认知缺陷（19.7%，95% CI 8.8-33.4）、记忆障碍（17.5%，95% CI 8.6-29.6）和味觉或嗅觉丧失（15.7%，95% CI 6.6-27.8）最常见普遍报道。

#### Effect of clinical characteristics and demographic factors on neuropsychiatric symptoms

#### 临床特征和人口统计学因素对神经精神症状的影响

We did subgroup analysis to examine the longitudinal resolution of neuropsychiatric symptoms (Fig. [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig4/), Supplementary Fig. [S16](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)), neurological symptom decreased from 22.0% (95% CI 17.1–27.3, at <3 months), and 22.5% (95% CI 13.4–33.0, at 3–6 months) to 15.8% (95% CI 13.4–18.4, at 6–12 months) (_P_ = 0.04). Survivors reported declining psychiatric symptoms of 23.6% (95% CI 16.1–32.0, at <3 months), 20.1% (95% CI 11.2–30.8, at 3–6 months) and 18.0% (95% CI 12.5–24.3, at 6–12 months), although there was no significant difference across these time-points. Symptom of PTSD, however, was found to significantly resolve over the time, from 23.1% (95% CI 10.9–37.9) at <3 months, to 16.2% (95% CI 9.7–24.0) at 3–6 months and 7.4% (95% CI 4.3–11.2) at 6–12 months (_p_ < 0.01). Specifically, the most prevalent psychiatric outcomes at 6–12 months after initial infection were anxiety (15.4%, 95% CI 8.0–24.6), depression (12.4%, 95% CI 5.8–21.1) and sleep disturbance (12.3%, 95% CI 4.8–22.6). For neurological symptoms, cognitive deficits (22.2%, 95% CI 19.6–25.0), dizziness (19.5%, 95% CI 0.5–55.1) and loss of taste or smell (17.1%, 95% CI 4.9–34.6%) were most prevalent at the 6–12 month time-point.

我们进行了亚组分析以检查神经精神症状的纵向消退（图 [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig4/) ，补充图 [S16](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) ），神经症状从 22.0%（95% CI 17.1-27.3，<3 个月）和 22.5%（95% CI 13.4–33.0，在 3–6 个月）至 15.8%（95% CI 13.4–18.4，在 6–12 个月）（ _P_ \= 0.04）。 幸存者报告精神症状下降 23.6%（95% CI 16.1-32.0，在 <3 个月）、20.1%（95% CI 11.2-30.8，在 3-6 个月）和 18.0%（95% CI 12.5-24.3，在6-12 个月），尽管这些时间点之间没有显着差异。 然而，PTSD 的症状被发现随着时间的推移显着消退，从 <3 个月时的 23.1% (95% CI 10.9–37.9) 到 3–6 个月时的 16.2% (95% CI 9.7–24.0) 和 7.4% (95% CI 4.3–11.2) 在 6–12 个月 ( _p_ < 0.01)。 具体而言，初次感染后 6-12 个月最普遍的精神结局是焦虑（15.4%，95% CI 8.0-24.6）、抑郁（12.4%，95% CI 5.8-21.1）和睡眠障碍（12.3%，95%）置信区间 4.8–22.6）。 对于神经系统症状，认知缺陷（22.2%，95% CI 19.6-25.0）、头晕（19.5%，95% CI 0.5-55.1）和味觉或嗅觉丧失（17.1%，95% CI 4.9-34.6%）最常见在 6-12 个月的时间点普遍存在。

[](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig4/)

[![包含图片、插图等的外部文件。 
对象名称是 41380_2022_1614_Fig4_HTML.jpg](41380_2022_1614_Fig4_HTML.jpg "点击图片放大")](https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=9168643_41380_2022_1614_Fig4_HTML.jpg)

**The pooled prevalence of neuropsychiatric sequelae and subgroup analysis.**

83 studies investigated neuropsychiatric symptoms, prevalence of the specific symptoms were as follows: 19.7% for any psychiatric illness, 18.3% for depression, 17.9% for PTSD, 16.2% for anxiety and 13.5% for sleep disturbance in psychiatric symptoms and 18.7% for any neurological symptoms, 19.7% for cognitive deficits, 17.5% for memory impairment, and 15.7% for loss of taste or smell in neurological symptoms. Patients were found to exhibit neuropsychiatric symptoms even 6 months after infection and mild patients who were not hospitalized were also presented with neuropsychiatric syndromes.

83 项研究调查了神经精神症状，特定症状的患病率如下：任何精神疾病占 19.7%，抑郁占 18.3%，创伤后应激障碍占 17.9%，焦虑占 16.2%，睡眠障碍占 13.5%，任何精神症状占 18.7%神经系统症状，19.7%为认知缺陷，17.5%为记忆障碍，15.7%为神经系统症状中味觉或嗅觉丧失。 患者甚至在感染后 6 个月被发现表现出神经精神症状，未住院的轻度患者也出现神经精神综合征。

Subgroup analysis for the severity of the acute infection were conducted (Fig. [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig4/)). The prevalence of sequelae in specific neuropsychiatric symptom including any psychiatric symptoms and sleep disturbance increased according to the severity of the acute infection, from the lowest prevalence in asymptomatic community subjects to the highest prevalence among those who were hospitalized as severely or critically ill patients. Sleep disturbance was more commonly found in severely or critically ill subjects (21.8%, 95% CI 6.6–42.2) compared to those with hospitalized with mild or moderate acute illness (10.9%, 95% CI 1.6–26.4), and asymptomatic or community-based patients (0.7%, 95% CI 0.09–1.8) (_p_ < 0.01). In contrast, anxiety was more frequent in asymptomatic or community-based patients (28.5%, 95% CI 23.9–33.3), compared to those mildly or moderately unwell hospitalized patients (20.7%, 95% CI 9.4–34.8) and severely or critically ill patients (12.9%, 95% CI 7.3–19.6) (_p_ < 0.01). Notably, mild cases who were not hospitalized experienced a wide variety of neuropsychiatric symptoms months after recovery. Among the mild cases, the most common outcomes were memory impairment (37.5%, 95% CI 28.1–47.5), anxiety (28.5%, 95% CI 23.9–33.3) and depression (14.7%, 95% CI 2.2–35.0). (Fig. [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig4/), Supplementary Fig. [S20](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)).

对急性感染的严重程度进行了亚组分析（图 [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig4/) ）。 根据急性感染的严重程度，包括任何精神症状和睡眠障碍在内的特定神经精神症状后遗症的患病率增加，从无症状社区受试者的最低患病率到作为重症或危重症住院患者的最高患病率。 与因轻度或中度急性疾病住院的患者（10.9%，95% CI 1.6-26.4）以及无症状或社区患者相比，重症或危重患者（21.8%，95% CI 6.6-42.2）更常见睡眠障碍基于患者 (0.7%, 95% CI 0.09–1.8) ( _p_ < 0.01)。 相比之下，与轻度或中度不适的住院患者 (20.7%, 95% CI 9.4-34.8) 和重度或危重患者相比，无症状或社区患者 (28.5%, 95% CI 23.9-33.3) 的焦虑更常见病患者 (12.9%, 95% CI 7.3–19.6) ( _p_ < 0.01)。 值得注意的是，未住院的轻度病例在康复数月后出现了各种各样的神经精神症状。 在轻度病例中，最常见的结局是记忆障碍（37.5%，95% CI 28.1-47.5）、焦虑（28.5%，95% CI 23.9-33.3）和抑郁（14.7%，95% CI 2.2-35.0）。 （图。 [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig4/) ，补充图 [S20](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) ）。

Subgroup analyses were further performed regarding the mean age, proportion of male participants and income level regarding neuropsychiatric symptoms, (Fig. [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig4/), Supplementary Fig. [S16](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)–[S20](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)). Older people suffered more from dizziness (age ≥60 years: 73.7%, 95% CI 64.3–82.1 vs. age <60: 6.8%, 95% CI 2.2–13.5, _p_ < 0.01), whereas younger adults are at higher risk of olfactory dysfunction (age <60: 17.4%, 95% CI 10.7–25.3 vs. age ≥60: 8.4%, 95% CI 4.5–13.3, _p_ = 0.04). A higher proportion of male participants had a significant effect on the prevalence of PTSD (male proportion ≥ 50%: 20.5, 95% CI 12.4–30.0 vs. male proportion < 50%: 10.6, 95% CI 6.4–15.7, _p_ = 0.04) and concentration impairment (male proportion ≥ 50%: 30.6, 95% CI 27.0–34.4 vs. male proportion < 50%: 8.9, 95% CI 2.9–17.6, _p_ < 0.01). In addition, COVID-19 survivors who lived in a high-income country had an increased risk of, concentration impairment (high-income country: 15.3, 95% CI 7.3–25.5 vs. middle- or low-income country: 1.0, 95% CI 0.7–1.4, _p_ < 0.01), dizziness (high-income country: 18.1, 95% CI 4.0–39.3 vs. middle- or low-income country: 2.5, 95% CI 1.1–4.2, _p_ = 0.03) and gustatory dysfunction (high-income country: 13.1, 95% CI 8.1–19.1 vs. middle- or low-income country: 3.2, 95% CI 1.3–5.7, _p_ < 0.01), whereas cognitive deficits were more found in middle- or low-income country (high-income country: 14.3, 95% CI 4.2–28.8 vs. middle- or low-income country: 38.4, 95% CI 31.8–45.1, _p_ < 0.01).

就神经精神症状的平均年龄、男性参与者的比例和收入水平进一步进行亚组分析（图 [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig4/) ，补充图 [S16](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) \- [S20](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) ）。 老年人更容易头晕（年龄≥60 岁：73.7%，95% CI 64.3–82.1 vs. 年龄 <60 岁：6.8%，95% CI 2.2–13.5， _p_ < 0.01），而年轻人头晕的风险更高嗅觉功能障碍（年龄 <60：17.4%，95% CI 10.7-25.3 vs. 年龄≥60：8.4%，95% CI 4.5-13.3， _p_ \= 0.04）。 较高比例的男性参与者对 PTSD 的患病率有显着影响（男性比例 ≥ 50%：20.5，95% CI 12.4–30.0 对比男性比例 < 50%：10.6，95% CI 6.4–15.7， _p_ \= 0.04 ) 和注意力障碍（男性比例 ≥ 50%：30.6，95% CI 27.0–34.4 vs. 男性比例 < 50%：8.9，95% CI 2.9–17.6， _p_ < 0.01）。 此外，生活在高收入国家的 COVID-19 幸存者出现注意力不集中的风险增加（高收入国家：15.3，95% CI 7.3–25.5 对比中等或低收入国家：1.0，95 % 置信区间 0.7–1.4， _p_ < 0.01）、头晕（高收入国家：18.1，95% CI 4.0-39.3 对比中等或低收入国家：2.5，95% CI 1.1-4.2， _p_ \= 0.03）和味觉功能障碍（高收入 国家国家：13.1，95% CI 8.1–19.1 对比中等或低收入国家：3.2，95% CI 1.3–5.7， _p_ < 0.01），而认知缺陷更多见于中等或低收入国家（高-收入国家：14.3，95% CI 4.2–28.8 对比中等或低收入国家：38.4，95% CI 31.8–45.1， _p_ < 0.01）。

### Predictive risk factors and biomarkers

### 预测性风险因素和生物标志物

To help clinicians efficiently identify survivors most at risk of long-term sequelae, we summarized the evidence of potential predictive risk factors and biomarkers in Fig. [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig5/) and Supplementary Table [S3](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1). Potential risk factors that were identified were categorized into three groups: pre-illness, during acute illness and during the convalescent stage. In terms of pre-illness factors, individuals who were older \[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4), [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33)\], male \[[5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5), [34](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR34)\] and had pre-existing conditions such as pulmonary disease (particularly COPD) \[[5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5), [34](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR34)\], those with a history of psychiatric illness \[[35](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR35)\], and cigarette smokers \[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4), [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5)\] had a significantly higher risk of medium- or long-term COVID-19 sequelae. During the acute illness stage, those who suffered from severe COVID-19 illness (admitted to the ICU or requiring mechanical ventilation) \[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4), [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5), [36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36), [37](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR37)\], required longer hospital stays \[[38](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR38)–[41](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR41)\] and those with abnormal objective test results (higher peak CT pneumonia score \[[33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33)\], higher level of CRP \[[5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5), [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33), [34](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR34)\], elevated white blood cell count \[[37](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR37), [42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42)\], lower albumin \[[33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33)\], higher level of D-dimer \[[33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33)\], higher level of glucose \[[33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33)\] or higher level of ALT \[[37](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR37), [42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42)\]) were at greater risk of long-term sequelae. SARS-COV-2-associated cytokines, including interleukin (IL)-6, IL-1b, tumor necrosis factor (TNF), and IL-17, which are known to disrupt the blood-brain barrier and could facilitate the entry of the virus and consequent brain damage, were associated with persistent neurological symptoms \[[43](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR43)\]. After discharge from the hospital, survivors who had no access to oxygen supplementation or those with abnormal objective test results (abnormal pulmonary function, especially DLCO \[[38](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR38), [44](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR44)\], decreasing D-dimer \[[12](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR12)\], or abnormal cardiac magnetic resonance (CMR) findings \[[45](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR45)\]) were also at higher risk of experiencing long-term effects of COVID-19. Furthermore, patients who report living with children \[[36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36)\] and perceived stigma \[[36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36)\] involving verbal abuse and rejection from family, relatives, neighbors, and community were also at increased risk.

为了帮助临床医生有效地识别最有可能出现长期后遗症的幸存者，我们在图 [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig5/) 和补充表 [S3](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) 中总结了潜在预测风险因素和生物标志物的证据。 已确定的潜在风险因素分为三组：疾病前期、急性疾病期间和恢复期。 就病前因素而言，年龄较大 \[ [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4) , [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33) \] 、男性 \[ [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5) 、 [34](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR34) \] 并且有肺部疾病（特别是 COPD） \[ [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5) 、 [34](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR34) \] 等既往病史的个体、有精神病史的个体疾病 \[ [35](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR35) \] 和吸烟者 \[ [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4) 4、5 [。](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5) 患中长期 COVID-19 后遗症的风险明显更高 在急性疾病阶段，患有严重 COVID-19 疾病（入住 ICU 或需要机械通气）\[4、5、36、37 [时间](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4) 的 [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5) 住院 [38-41](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36) 更长 [患者](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR37) \[ [需要](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR38) 、 [患者](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR41) \]以及客观测试异常的 结果（更高的峰值 CT 肺炎评分 \[ [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33) 水平的 CRP \[ [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5) 、 [5、33、34](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33) \] 、 [更高](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR34) 升高的白细胞计数 \[ [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR37) \] 、 [37、42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42) 、较低的白蛋白 \[ [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33) 较高水平的 D-二聚体 \[ [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33) 水平的葡萄糖 \[ [37、42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33) \] 或较高水平的 ALT \[ [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR37) 、 [较高](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42) \]）具有更大的长期后遗症风险。 SARS-COV-2 相关细胞因子，包括白介素 (IL)-6、IL-1b、肿瘤坏死因子 (TNF) 和 IL-17，已知它们会破坏血脑屏障并可能促进病毒和随之而来的脑损伤，与持续的神经系统症状有关 \[ [43](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR43) \]。 出院后，无法补充氧气或客观检查结果异常（肺功能异常，尤其是 DLCO \[38、44 [、](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR38) D- [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR44) 二聚体 \[ [12](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR12) \] 降低或心脏磁共振 (CMR) 异常） 的幸存者调查结果 \[ [45](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR45) \]) 也有更高的风险经历 COVID-19 的长期影响。 \] 的患者， [此外，报告与孩子同住 \[ 36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36) \] 并感知耻辱感 \[ [36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36) 包括来自家人、亲戚、邻居和社区的辱骂和拒绝，也面临更高的风险。

[](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/figure/Fig5/)

[![包含图片、插图等的外部文件。 
对象名称是 41380_2022_1614_Fig5_HTML.jpg](41380_2022_1614_Fig5_HTML.jpg "点击图片放大")](https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=9168643_41380_2022_1614_Fig5_HTML.jpg)

**Framework of long-term sequelae, risk factors, and prevention and intervention strategies for long COVID-19.**

Potential risk facotrs were categorized into three groups: the pre-illness group included age, sex and pre-existind conditions; the acute illness stage group included severity of illness, hospital length and abnormal objective tests during hospitalization; the convalescent stage included access to oxygen supplementation, abnormal objective tests during follow up and perception of stigma from community.

潜在风险因素分为三组：患病前组包括年龄、性别和既往病史； 急性病期组包括病情严重程度、住院时间和住院期间客观检查异常； 恢复期包括获得氧气补充、随访期间的异常客观测试和社区对耻辱感的感知。

### Quality control and publication bias

### 质量控制和发表偏倚

According to the quality assessment criteria, twelve studies (7.9%) were graded as high quality, 124 (82.2%) as medium quality, and 15 (9.9%) as low quality (Supplementary Table [S2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)). Meta-regression found no effect of study quality on the estimation of sequelae prevalence.

根据质量评估标准，12 项研究 (7.9%) 被评为高质量，124 项 (82.2%) 被评为中等质量，15 项 (9.9%) 被评为低质量（补充表 [S2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) ）。 元回归发现研究质量对后遗症患病率的估计没有影响。

We observed an effect of small study size when estimating the prevalence of abnormal pulmonary function tests, generalized symptoms, and respiratory and neurological sequelae across studies (Egger’s test: _p_ < 0.001, Supplementary Table [S4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)) but not that of other organ systems (Egger’s test: _p_ > 0.05) and funnel plot (Supplementary Fig. [21](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)). Applying the leave-one-out sensitivity analysis did not significantly alter the pooled estimates of the prevalence of sequelae, indicating that no individual study significantly influenced the results (Supplementary Fig. [S22](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)).

我们在估计研究中异常肺功能测试、全身症状以及呼吸系统和神经系统后遗症的患病率时观察到小规模研究的影响（Egger 检验： _p_ < 0.001，补充表 [S4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) ），但其他器官系统没有（Egger 检验: _p_ \> 0.05) 和漏斗图（补充图 [21](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) ）。 应用留一法敏感性分析并未显着改变后遗症患病率的汇总估计，表明没有个体研究显着影响结果（补充图 [S22](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) ）。

## Discussion

## 讨论

This study is, to our knowledge, the largest and most wide-ranging systematic review and meta-analysis to date, comprehensively summarizing current evidence on the long-term physical and mental sequelae of COVID-19 in the convalescent phase. Our results found that approximately half of survivors had multiple organ sequelae after discharge from the hospital and within up to 12 months of follow-up. Unsurprisingly, the most common sequelae involved the respiratory system, followed by generalized symptoms, psychiatric symptoms, and neurological symptoms, which were also of similarly high prevalence. Additionally, our study is also the first to perform subgroup analyses and found that the prevalence and burden of long-term physical and mental sequelae among COVID-19 survivors increased with older age, higher male proportion, living in a high-income country, severity in acute infection, and decreased with the extension of follow-up time. Prospective cohort studies with large sample sizes that aim to further characterize the long-term sequelae of COVID-19 are needed, especially in lower-income countries. Future studies with large sample sizes, long-term follow-up and exploring biomarkers and underlying pathological mechanisms will be addressed to better understand, prevent and heal physical conditions and mental well-being.

据我们所知，这项研究是迄今为止规模最大、范围最广的系统回顾和荟萃分析，全面总结了目前关于 COVID-19 康复期长期身心后遗症的证据。 我们的研究结果发现，大约一半的幸存者在出院后和长达 12 个月的随访期间出现多器官后遗症。 不出所料，最常见的后遗症涉及呼吸系统，其次是全身症状、精神症状和神经系统症状，这些症状的发生率也同样很高。 此外，我们的研究还率先进行了亚组分析，发现 COVID-19 幸存者长期身心后遗症的患病率和负担随着年龄的增长、男性比例较高、生活在高收入国家、严重程度的增加而增加在急性感染中，随随访时间的延长而降低。 需要大样本的前瞻性队列研究，旨在进一步表征 COVID-19 的长期后遗症，特别是在低收入国家。 未来将开展大样本、长期随访和探索生物标志物和潜在病理机制的研究，以更好地了解、预防和治愈身体状况和心理健康。

Respiratory abnormalities remain a key issue in survivors of COVID-19. Although only a quarter of survivors reported respiratory symptoms, including dyspnea, cough and chest distress, more than 50% of survivors displayed objective persistent impairment on lung CT scans and pulmonary function tests. Furthermore, previous studies have reported that lower lymphocytes and asthma during hospitalization were associated with the presence of long-term subjective respiratory symptoms \[[40](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR40), [42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42)\]. This finding indicates that it is necessary to carry out CT scans and pulmonary function tests during follow-up of COVID-19 in the convalescent phase. Given that the potential risk of pulmonary injury may last months to years \[[46](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR46)\], further research is required to confirm the risk factors and mechanism for respiratory sequelae and to identify treatments that prevent pulmonary fibrosis in survivors of COVID-19 \[[47](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR47)\]. Our study also reported significant cardiovascular sequelae associated with SARS-COV-2 infection, with 14.8% of survivors reporting cardiovascular symptoms and palpitation being the most common symptoms. Unlike previous studies that indicate an association between cardiovascular injury and fatal cases among SARS and MERS patients \[[31](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR31), [48](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR48), [49](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR49)\], some studies found that cardiac conditions are mostly mild in COVID-19 survivors \[[40](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR40), [50](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR50)\]. Our study demonstrated that 28.3% of patients experienced lasting fatigue after recovering from their acute illness, which is similar to previous findings in SARS patients, approximately one-third of whom reported persistent fatigue within the follow-up period of 18 to 40 months post-infection \[[17](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR17), [51](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR51)\]. A lengthy post-disease fatigue will not only impair the quality of life of individuals but also have adverse impacts on employers and governments; thus, multidisciplinary input to manage fatigue should be of particular concern.

呼吸系统异常仍然是 COVID-19 幸存者的一个关键问题。 尽管只有四分之一的幸存者报告呼吸困难、咳嗽和胸闷等呼吸系统症状，但超过 50% 的幸存者在肺部 CT 扫描和肺功能测试中显示出客观的持续性损伤。 此外，先前的研究报告称，住院期间淋巴细胞减少和哮喘与长期主观呼吸道症状的存在有关 [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR40) 40、42 [\[](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42) 。 这一发现表明，在 COVID-19 的恢复期随访期间，有必要进行 CT 扫描和肺功能检查。 鉴于肺损伤的潜在风险可能持续数月至数年 \[ [46](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR46) \]，需要进一步研究以确认呼吸系统后遗症的危险因素和机制，并确定预防 COVID-19 幸存者肺纤维化的治疗方法 \[ [47](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR47) \]。 我们的研究还报告了与 SARS-COV-2 感染相关的严重心血管后遗症，14.8% 的幸存者报告心血管症状，心悸是最常见的症状。 不同于以往的研究表明，SARS 和 MERS 患者的心血管损伤与死亡病例之间存在关联 \[ [31](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR31) , [48](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR48) , [49](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR49) \]，一些研究发现 COVID-19 幸存者的心脏状况大多较轻 \[ [40](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR40) , [50](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR50) \]。 我们的研究表明，28.3% 的患者在从急性疾病中恢复后经历了持久的疲劳，这与之前在 SARS 患者中的发现相似，其中约三分之一的患者报告在 SARS 后 18 至 40 个月的随访期内持续疲劳。感染 \[ [17](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR17) , [51](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR51) \]。 长期的病后疲劳不仅会损害个人的生活质量，还会对雇主和政府产生不利影响； 因此，应特别关注管理疲劳的多学科投入。

COVID-19 is also anticipated to take a toll on the mental and neuropsychiatric health of survivors in the long term \[[43](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR43)\]. Approximately one-fifth of COVID-19 survivors in this review demonstrate psychiatric symptoms during the 12 months after recovery. These estimates are similar to those in survivors of SARS and MERS, in whom psychiatric illness may linger beyond 6 months \[[17](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR17), [51](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR51), [52](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR52)\]. Neuroinflammation induced by SARS-COV-2 infection and reduction of neurotransmitters related to interferon- or IL-based immunotherapy may correlate with a prolonged psychiatric syndrome. In addition, studies demonstrated that increased public restrictions, stressful medical care in hospital, concerns about infecting others as well as stigma may have considerable impacts on the mental health of survivors \[[53](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR53)–[55](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR55)\]. Depression following pandemics is a most significant public health concern. Our study reported a long-term prevalence of 18.3%, and another study concerning COVID-19 suggested an overall depression prevalence of 27.9% \[[53](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR53)\]. It is also important to note that even mildly affected patients who didn’t require to hospital can exhibit a high prevalence of long term psychiatric symptoms, including anxiety and depression.

从长远来看，COVID-19 预计还会对幸存者的精神和神经精神健康造成损害 \[ [43](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR43) \]。 在本次审查中，大约五分之一的 COVID-19 幸存者在康复后的 12 个月内表现出精神症状。 这些估计与 SARS 和 MERS 幸存者的估计相似，在这些幸存者中，精神疾病可能会持续 6 个 [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR17) 17,51,52 [月](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR51) 以上 [\[](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR52) 。 SARS-COV-2 感染引起的神经炎症和与基于干扰素或白介素的免疫疗法相关的神经递质减少可能与长期的精神综合症有关。 此外，研究表明，公共限制的增加、医院的医疗护理压力、对感染他人的担忧以及耻辱感可能对幸存者的心理健康产生相当大的影响 \[ [53](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR53) – [55](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR55) \]。 大流行后的抑郁症是最重要的公共卫生问题。 我们的研究报告了 18.3% 的长期患病率，另一项关于 COVID-19 的研究表明总体抑郁症患病率为 27.9% \[ [53](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR53) \]。 同样重要的是要注意，即使是不需要住院的轻度患者也可能表现出高患病率的长期精神症状，包括焦虑和抑郁。

In our study, neurological consequences were also identified, with an estimated prevalence of 11.4%. Memory impairment, cognitive deficits and loss of taste or smell were the predominant symptoms in this system. Among them, 15.1% and 10.6% of patients experience persistent olfactory and gustatory dysfunction, respectively, after recovery, which are highly specific to COVID-19 infection. Such neurological deficits may be due to brain damage caused by neuroinflammation and hypoxic injury in relation to viral invasion \[[56](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR56), [57](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR57)\]. A study investigated brain image changes in the UK Biobank participants and found significant longitudinal reduction in gray matter thickness among COVID-19 survivors. Studies indicated that alterations of olfactory and memory function may predict long term consequence such as Alzheimer’s disease or other forms of dementia \[[58](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR58), [59](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR59)\]. More efforts aimed to elucidate the mechanisms of and develop early screening and interventions for the psychiatric and neurological sequelae of COVID-19 need to be addressed. One such study is the long-term database and biobank launched in the United States to collect information about neurological problems specifically associated with COVID-19 \[[60](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR60)\].

在我们的研究中，还确定了神经系统后果，估计患病率为 11.4%。 记忆障碍、认知缺陷和味觉或嗅觉丧失是该系统的主要症状。 其中，康复后分别有15.1%和10.6%的患者出现持续的嗅觉和味觉功能障碍，这对COVID-19感染具有高度特异性。 这种神经功能缺陷可能是由于与病毒入侵相关的神经炎症和缺氧损伤引起的脑损伤 \[ [56](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR56) , [57](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR57) \]。 一项研究调查了英国生物银行参与者的大脑图像变化，发现 COVID-19 幸存者的灰质厚度纵向显着减少。 研究表明，嗅觉和记忆功能的改变可以预测长期后果，例如阿尔茨海默病或其他形式的痴呆症 [58、59](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR58) \[ [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR59) 。 需要解决更多旨在阐明 COVID-19 精神和神经后遗症机制并制定早期筛查和干预措施的努力。 其中一项研究是在美国启动的长期数据库和生物库，以收集与 COVID-19 相关的神经系统问题的信息 \[ [60](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR60) \].

Since the medical community has begun to recognize those affected by long-term COVID-19 sequelae \[[7](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR7)\], we summarize the relevant factors in the included articles to identify the potential predictive biomarkers for different sequelae. First, people who are male \[[34](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR34)\], with pre-existing pulmonary disease \[[34](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR34)\], and severe acute disease during hospitalization with COVID-19 \[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4), [34](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR34)\], who do not receive oxygen treatment during follow-up \[[12](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR12)\] and have decreasing D-dimer levels \[[12](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR12)\] are at higher risk of having any sequelae after discharge from the hospital. Patients who are older, have a longer incubation period, higher peak CT pneumonia score, abnormal biomarkers (lower albumin level \[[33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33)\], higher urea nitrogen level \[[33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33)\], higher serum sodium concentration \[[33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33)\], higher glucose \[[33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33)\], higher CRP \[[33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33)\], higher D-dimer \[[33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33)\]), longer hospital stay length \[[38](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR38), [39](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR39)\], treated with oxygen during hospitalization \[[38](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR38)\], and with abnormal pulmonary function detected during follow-up tend to have long-term abnormal CT manifestations. Female patients \[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4), [38](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR38)\] with chronic kidney disease \[[5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5)\], smoking history or COPD history \[[5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5), [36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36)\], who have been admitted to the ICU or have severe COVID-19 \[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4), [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5)\] in the hospital, would be at higher risk of long-term abnormal pulmonary function. In addition, female patients with older age \[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4)\] who have abnormal biomarkers during hospitalization, including higher AST \[[42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42)\], ALT \[[42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42)\] and serum troponin-I \[[42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42)\], or detected with abnormal pulmonary function tests \[[38](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR38), [44](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR44)\] during follow-up, are more likely to have persistent generalized symptoms such as fatigue. Meta-regression analyses based on age, male proportion, and follow-up duration as continuous variables were also performed, and the results supported these findings of the subgroup analyses (Supplementary Table [S5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1)). Patients with a history of pulse ≥90 beats per min during hospitalization \[[40](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR40)\], had symptoms of dyspnea \[[40](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR40)\] and had lower lymphocytes \[[42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42)\] during hospitalization, and those who had high-sensitivity troponin T markers \[[45](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR45)\] and abnormal CMR findings \[[45](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR45)\] tended to be vulnerable to cardiovascular-related sequelae.

由于医学界已经开始认识到那些受长期 COVID-19 后遗症影响的人 \[ [7](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR7) \]，我们总结了纳入文章中的相关因素，以确定不同后遗症的潜在预测生物标志物。 首先，男性 \[ [34](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR34) \]、既往患有肺部疾病 \[ [34](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR34) \-19 住院期间患有严重急性疾病 \[4、34 [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4) ， [\]、在因COVID](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR34) 并且在随访期间未接受氧气治疗 \[ [12](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR12) \] 和D-二聚体水平降低 \[ [12](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR12) \] 出院后出现任何后遗症的风险更高。 年龄较大、潜伏期较长、峰值 CT 肺炎评分较高、生物标志物异常（较低的白蛋白水平 \[ [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33) \]、较高的尿素氮水平 \[ [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33) \]、较高的血清钠浓度 \[ [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33) \]、较高的葡萄糖 \[ [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33) \]、较高的CRP \[ [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33) \]、较高的 D-二聚体 \[ [33](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR33) \]）、较长的住院时间 \[ [38](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR38) 、 [39](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR39) \]、住院期间接受氧气治疗 \[ [38](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR38) \] 以及随访期间检测到的肺功能异常往往有长期异常CT表现。 女性患者 \[ [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4) , [38](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR38) \] 患有慢性肾病 \[ [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5) \]、吸烟史或 COPD 病史 \[ [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5) , [36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36) \]，已入住 ICU 或在医院有严重 COVID-19 \[ [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4) , [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5) \] 的人，风险更高长期肺功能异常。 此外， [的年龄较大 \[ 4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4) 住院期间生物标志物异常 [\] 的女性患者 \[ 42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42) \]、ALT\[ [42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42) \] 和血清肌钙蛋白-I \[ [42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42) 或肺功能检查异常 \[ [38、44](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR38) ， [\]较高](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR44) \]在随访期间，更可能有持续的全身症状，如疲劳。 还进行了基于年龄、男性比例和随访持续时间作为连续变量的元回归分析，结果支持亚组分析的这些发现（补充表 [S5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#MOESM1) ）。 住院期间脉搏≥90 次/分的患者 \[ [40](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR40) \]，住院期间有呼吸困难症状 \[ [40](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR40) \] 和淋巴细胞 \[ [42](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR42) \] 降低，以及高敏肌钙蛋白 T 标志物 \[ [45](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR45) \] 和 CMR 异常 的患者发现 \[ [45](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR45) \] 容易受到心血管相关后遗症的影响。

Some factors increased the risk of long-term psychiatric and neurological problems among COVID-19 survivors, including patients who suffer from a history of psychiatric illness or pulmonary disease \[[5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5), [35](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR35), [61](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR61)\], who have severe acute COVID-19 \[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4), [62](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR62)\], who are not treated with corticosteroids in the hospital \[[36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36)\], who live with children \[[36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36)\], and who perceive discrimination after discharge \[[36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36)\]. In addition, sleep disturbance, anxiety and depression were most commonly found in female patients, whereas PTSD was more common in male patients \[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4), [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5), [63](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR63)\]. Previous studies suggested that quarantine and delays in returning to work were also associated with worse mental health outcomes among infected individuals during the COVID-19 outbreak \[[14](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR14), [53](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR53)\]. For digestive sequelae, the most influential factors included elevation of certain biomarkers (CD4, CRP, ALT, white blood cells, lymphocytes and procalcitonin) and treatments with corticosteroids and PPIs \[[37](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR37)\]. Although predictive factors and biomarkers have been proposed in some follow-up studies, further prospective studies that systematically correlate risk factors with clinical outcomes should be established. To address these key questions, updated results from ongoing, prospective, longitudinal studies involving interdisciplinary and multinational researchers are eagerly awaited \[[47](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR47), [64](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR64)\].

\-19 幸存者出现长期精神和神经问题的风险，包括患有精神疾病或肺部疾病病史的患者 \[ [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5) ， [\[](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR35) 5、35、61 [一些因素增加了COVID](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR61) 他们患有严重的急性 COVID-19 [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4) ， [62](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR62) \]、未在医院接受皮质类固醇治疗的患者 \[ [36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36) \]、与孩子同住 [的患者 \[ 36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36) \] 以及出院后感到歧视 [的患者 \[ 36](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR36) \]。 此外，睡眠障碍、焦虑和抑郁最常见于女性患者，而 PTSD 更常见于 [4、5、63](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR4) \[ [患者](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR5) 男性 [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR63) 。 先前的研究表明，在 COVID-19 爆发期间，隔离和延迟重返工作岗位也与受感染者较差的心理健康结果有关 [\]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR14) \[ [14、53](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR53) 。 对于消化后遗症，影响最大的因素包括某些生物标志物（CD4、CRP、ALT、白细胞、淋巴细胞和降钙素原）的升高以及皮质类固醇和 PPI 的治疗 \[ [37](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR37) \]。 尽管在一些后续研究中提出了预测因素和生物标志物，但应建立进一步的前瞻性研究，将风险因素与临床结果系统地关联起来。 为了解决这些关键问题，热切期待涉及跨学科和跨国研究人员的正在进行的、前瞻性的纵向研究的最新结果 \[ [47](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR47) , [64](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR64) \].

The findings from this study should be interpreted with caution in the context of its limitations. A weakness of the currently available data, and therefore of this review, was the high heterogeneity between studies, with most I-squared estimates >50%. The heterogeneity may be due to different definitions of cases, a variety of diagnostic criteria, and different follow-up durations across studies. Subgroup analysis has shown that age, sex proportion, region of studies, severity of acute infection and follow-up duration all have impacts on the overall estimations of the prevalence and are likely to explain some of these variations. Endeavors on the internationally agreed definition and management of long-term sequelae among COVID-19 survivors will help decrease heterogeneity of prevalence across studies. Second, the estimated prevalence of any symptoms in a specific organ system is based on self-reported, and neuropsychiatric symptoms are mainly self-reported. Although we pooled the subjective symptoms and objective examination tests for the respiratory and cardiovascular system, the objectively detected evidence is limited, such as only one study reported cardiac inflammation. More prospective cohort studies with larger sample sizes, longer follow up periods and objective examinations, such as brain imaging are needed. Third, these results are need interpreted cautiously, because we could not verify that the self-report long-term sequelae was definitely caused by COVID-19 infection. Detailed medical evaluation of these patients is clearly needed to prevent or at least minimize the possibility that symptoms due to another disease are erroneously attributed to “long COVID” \[[65](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR65)\]. Fourth, our analysis found and reviewed only work done with the Alpha variant, and no study reported data on those who contracted the Delta or Omicron variants. We did not involve the effect of vaccination because of the limited number of studies reporting vaccination status. With the spread of new variants and with many people vaccinated, future studies would quite usefully observe whether similar symptom changes are found with these two new viral variants and whether the vaccines offer a layer of protection from these newer variants. Finally, risk stratification studies with biomarker-guided interventions and longer follow-up durations in larger populations could contribute to a better understanding of sequelae.

鉴于其局限性，应谨慎解释这项研究的结果。 当前可用数据以及本综述的一个弱点是研究之间的高度异质性，大多数 I 平方估计 >50%。 异质性可能是由于不同的病例定义、不同的诊断标准和不同的研究随访时间。 亚组分析表明，年龄、性别比例、研究区域、急性感染的严重程度和随访持续时间都会对患病率的总体估计产生影响，并可能解释其中的一些差异。 努力制定国际公认的 COVID-19 幸存者长期后遗症的定义和管理，将有助于降低各研究中流行率的异质性。 其次，特定器官系统中任何症状的估计患病率都是基于自我报告，而神经精神症状主要是自我报告。 尽管我们汇集了呼吸系统和心血管系统的主观症状和客观检查测试，但客观检测的证据是有限的，例如只有一项研究报告了心脏炎症。 需要更多样本量更大、随访时间更长和客观检查（例如脑成像）的前瞻性队列研究。 第三，这些结果需要谨慎解释，因为我们无法验证自我报告的长期后遗症是否存在 这 肯定是由 COVID-19 感染引起的。 显然需要对这些患者进行详细的医学评估，以防止或至少最大限度地减少将另一种疾病引起的症状错误地归因于“长 COVID”的可能性 \[ [65](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168643/#CR65) \]。 第四，我们的分析只发现并审查了使用 Alpha 变体完成的工作，没有研究报告有关感染 Delta 或 Omicron 变体的人的数据。 由于报告疫苗接种状况的研究数量有限，我们没有涉及疫苗接种的影响。 随着新变种的传播和许多人接种疫苗，未来的研究将非常有用地观察这两种新病毒变种是否发现了类似的症状变化，以及疫苗是否为这些新变种提供了一层保护。 最后，以生物标志物为指导的干预措施的风险分层研究和在更大人群中进行更长时间的随访可能有助于更好地了解后遗症。

## Conclusion

## 结论

This meta-analysis provides a comprehensive overview of the current state of knowledge of the long-term physical and mental sequelae of COVID-19 and the risk factors associated with it. Our findings suggest that about half patients who have recovered from COVID-19 have a burden of any long-term sequelae in the 12 months after hospital discharge. It is important to follow up with these patients and appropriately manage any persistent or emerging long-term sequelae in both physical and psychiatric domains. The interaction between physical and mental sequelae and the effect for the health and social well-being in the long term should be addressed in the future.

该荟萃分析全面概述了 COVID-19 的长期身心后遗症及其相关风险因素的当前知识状况。 我们的研究结果表明，大约一半的 COVID-19 康复患者在出院后 12 个月内会出现任何长期后遗症。 重要的是要跟进这些患者，并适当地处理身体和精神领域的任何持续或新出现的长期后遗症。 未来应解决身心后遗症之间的相互作用以及对健康和社会福祉的长期影响。

## Supplementary information

## 补充资料

## Author contributions

## 作者贡献

LL, YPB, and JS were responsible for the study design. NZ, YMZ, CL, LL, QDL, SYN, and HM were responsible for the literature search and study selection. NZ, YMZ, CL, QDL, and YPB were responsible for the data extraction and quality assessment. NZ, YMZ, WY, HQC, and LL were responsible for the statistical analysis and manuscript drafting. ALK, AL, WY, CL, MVV, TK, TTF, JLY, HQS, XDT, YML, MVV, JS, YPB, and LL were responsible for critical revision of the manuscript, and NZ, ALK, AL, TK, MVV, JS, YPB, and LL contributed to review and approval of the final version of the manuscript.

LL、YPB 和 JS 负责研究设计。 NZ、YMZ、CL、LL、QDL、SYN 和 HM 负责文献检索和研究选择。 NZ、YMZ、CL、QDL 和 YPB 负责数据提取和质量评估。 NZ、YMZ、WY、HQC 和 LL 负责统计分析和手稿起草。 ALK、AL、WY、CL、MVV、TK、TTF、JLY、HQS、XDT、YML、MVV、JS、YPB 和 LL 负责手稿的关键修订，NZ、ALK、AL、TK、MVV、 JS、YPB 和 LL 为审阅和批准手稿的最终版本做出了贡献。

## Funding

## 资金

This study was supported by grants from the National Key Research and Development Program of China (No. 2021YFC0863700, 2019YFA0706200) and the National Natural Science Foundation of China (No. 82171514, 81761128036, 81821092, and 31900805).

本研究得到国家重点研发计划（编号 2021YFC0863700、2019YFA0706200）和国家自然科学基金（编号 82171514、81761128036、81821092 和 31900805）的资助。

## Competing interests

## 利益争夺

The authors declare no competing interests.

作者声明没有竞争利益。

## Footnotes

## 脚注

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**出版商说明** 施普林格·自然 (Springer Nature) 对已出版地图和机构隶属关系中的管辖权声明保持中立。

These authors contributed equally: Na Zeng, Yi-Miao Zhao, Wei Yan.

These authors contributed equally: Na Zeng, Yi-Miao Zhao, Wei Yan.

## Contributor Information

## 贡献者信息

Jie Shi, Email: [nc.ude.umjb@eijihs](mailto:dev@null).

Jie Shi, Email: [nc.ude.umjb@eijihs](mailto:dev@null) .

Yan-Ping Bao, Email: [nc.ude.umjb@pyoab](mailto:dev@null).

Yan-Ping Bao, Email: [nc.ude.umjb@pyoab](mailto:dev@null) .

Lin Lu, Email: [nc.ude.umjb@ulnil](mailto:dev@null).

Lin Lu, Email: [nc.ude.umjb@ulnil](mailto:dev@null) .

## Supplementary information

## 补充资料

The online version contains supplementary material available at 10.1038/s41380-022-01614-7.

在线版本包含补充材料，网址为 10.1038/s41380-022-01614-7。

## References

## 参考

1\. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl J Med. 2020;382:727–33. doi: 10.1056/NEJMoa2001017. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092803/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/31978945)\] \[[CrossRef](https://doi.org/10.1056%2FNEJMoa2001017)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=N.+Engl+J+Med&title=A+novel+coronavirus+from+patients+with+pneumonia+in+China,+2019&author=N+Zhu&author=D+Zhang&author=W+Wang&author=X+Li&author=B+Yang&volume=382&publication_year=2020&pages=727-33&pmid=31978945&doi=10.1056/NEJMoa2001017&)\]

2\. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;324:782–93. doi: 10.1001/jama.2020.12839. \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32648899)\] \[[CrossRef](https://doi.org/10.1001%2Fjama.2020.12839)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=Pathophysiology,+transmission,+diagnosis,+and+treatment+of+coronavirus+disease+2019+(COVID-19):+A+review&author=WJ+Wiersinga&author=A+Rhodes&author=AC+Cheng&author=SJ+Peacock&author=HC+Prescott&volume=324&publication_year=2020&pages=782-93&pmid=32648899&doi=10.1001/jama.2020.12839&)\]

3\. Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of sars-cov-2. BMJ. 2020;371:m3862. doi: 10.1136/bmj.m3862. \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33097561)\] \[[CrossRef](https://doi.org/10.1136%2Fbmj.m3862)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMJ&title=Virology,+transmission,+and+pathogenesis+of+sars-cov-2&author=M+Cevik&author=K+Kuppalli&author=J+Kindrachuk&author=M+Peiris&volume=371&publication_year=2020&pages=m3862&pmid=33097561&doi=10.1136/bmj.m3862&)\]

4\. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220–32. doi: 10.1016/S0140-6736(20)32656-8. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833295/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33428867)\] \[[CrossRef](https://doi.org/10.1016%2FS0140-6736(20)32656-8)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=6-month+consequences+of+COVID-19+in+patients+discharged+from+hospital:+A+cohort+study&author=C+Huang&author=L+Huang&author=Y+Wang&author=X+Li&author=L+Ren&volume=397&publication_year=2021&pages=220-32&pmid=33428867&doi=10.1016/S0140-6736(20)32656-8&)\]

5\. Bellan M, Soddu D, Balbo PE, Baricich A, Zeppegno P, Avanzi GC, et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open. 2021;4:e2036142. doi: 10.1001/jamanetworkopen.2020.36142. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841464/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33502487)\] \[[CrossRef](https://doi.org/10.1001%2Fjamanetworkopen.2020.36142)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA+Netw+Open&title=Respiratory+and+psychophysical+sequelae+among+patients+with+COVID-19+four+months+after+hospital+discharge&author=M+Bellan&author=D+Soddu&author=PE+Balbo&author=A+Baricich&author=P+Zeppegno&volume=4&publication_year=2021&pages=e2036142&pmid=33502487&doi=10.1001/jamanetworkopen.2020.36142&)\]

6\. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–5. doi: 10.1001/jama.2020.12603. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349096/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32644129)\] \[[CrossRef](https://doi.org/10.1001%2Fjama.2020.12603)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=Persistent+symptoms+in+patients+after+acute+COVID-19&author=A+Carf%C3%AC&author=R+Bernabei&author=F+Landi&volume=324&publication_year=2020&pages=603-5&pmid=32644129&doi=10.1001/jama.2020.12603&)\]

7\. Kondratiuk AL, Pillay TD, Kon OM, Lalvani A. A conceptual framework to accelerate the clinical impact of evolving research into long COVID. Lancet Infect Dis. 2021;21:756–7. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062085/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33894903)\]

8\. Nehme M, Braillard O, Chappuis F, Courvoisier DS, Guessous I. Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting. Ann Intern Med. 2021;174:1252–60. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280535/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/34224254)\]

9\. Brito J, Silva B, da Silva P, Cortez-Dias N, Silva D, Agostinho J, et al. Cardiovascular complications of COVID-19. Heart Mind. 2020;4:67–74. doi: 10.4103/hm.hm\_28\_20. \[[CrossRef](https://doi.org/10.4103%2Fhm.hm_28_20)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Heart+Mind&title=Cardiovascular+complications+of+COVID-19&author=J+Brito&author=B+Silva&author=P+da+Silva&author=N+Cortez-Dias&author=D+Silva&volume=4&publication_year=2020&pages=67-74&doi=10.4103/hm.hm_28_20&)\]

10\. Allam H, Kinsara A, A Alrajawi A, Tuiama T. Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia. Heart Mind. 2020;4:123–5. doi: 10.4103/hm.hm\_34\_20. \[[CrossRef](https://doi.org/10.4103%2Fhm.hm_34_20)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Heart+Mind&title=Concomitant+acute+aortic+thrombosis+and+pulmonary+embolism+complicating+COVID-19+pneumonia&author=H+Allam&author=A+Kinsara&author=A+A+Alrajawi&author=T+Tuiama&volume=4&publication_year=2020&pages=123-5&doi=10.4103/hm.hm_34_20&)\]

11\. Huang Y, Tan C, Wu J, Chen M, Wang Z, Luo L, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21:163. doi: 10.1186/s12931-020-01429-6. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323373/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32600344)\] \[[CrossRef](https://doi.org/10.1186%2Fs12931-020-01429-6)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Respir+Res&title=Impact+of+coronavirus+disease+2019+on+pulmonary+function+in+early+convalescence+phase&author=Y+Huang&author=C+Tan&author=J+Wu&author=M+Chen&author=Z+Wang&volume=21&publication_year=2020&pages=163&pmid=32600344&doi=10.1186/s12931-020-01429-6&)\]

12\. Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. ‘Long-COVID’: A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020;76:396–8. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661378/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33172844)\]

13\. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. 2021;325:2015–6. doi: 10.1001/jama.2021.5612. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027932/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33825846)\] \[[CrossRef](https://doi.org/10.1001%2Fjama.2021.5612)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=Symptoms+and+functional+impairment+assessed+8+months+after+mild+COVID-19+among+health+care+workers&author=S+Havervall&author=A+Rosell&author=M+Phillipson&author=SM+Mangsbo&author=P+Nilsson&volume=325&publication_year=2021&pages=2015-6&pmid=33825846&doi=10.1001/jama.2021.5612&)\]

14\. Wang Y, Shi L, Que J, Lu Q, Liu L, Lu Z, et al. The impact of quarantine on mental health status among general population in China during the COVID-19 pandemic. Mol Psychiatry. 2021;26:4813–22. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821451/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33483692)\]

15\. Hui DS, Wong KT, Antonio GE, Tong M, Chan DP, Sung JJ. Long-term sequelae of SARS: Physical, neuropsychiatric, and quality-of-life assessment. Hong Kong Med J. 2009;15:21–3. \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/20393208)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Hong+Kong+Med+J&title=Long-term+sequelae+of+SARS:+Physical,+neuropsychiatric,+and+quality-of-life+assessment&author=DS+Hui&author=KT+Wong&author=GE+Antonio&author=M+Tong&author=DP+Chan&volume=15&publication_year=2009&pages=21-3&pmid=20393208&)\]

16\. Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: A 15-year follow-up from a prospective cohort study. Bone Res. 2020;8:8. doi: 10.1038/s41413-020-0084-5. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018717/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32128276)\] \[[CrossRef](https://doi.org/10.1038%2Fs41413-020-0084-5)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Bone+Res&title=Long-term+bone+and+lung+consequences+associated+with+hospital-acquired+severe+acute+respiratory+syndrome:+A+15-year+follow-up+from+a+prospective+cohort+study&author=P+Zhang&author=J+Li&author=H+Liu&author=N+Han&author=J+Ju&volume=8&publication_year=2020&pages=8&pmid=32128276&doi=10.1038/s41413-020-0084-5&)\]

17\. Lee SH, Shin HS, Park HY, Kim JL, Lee JJ, Lee H, et al. Depression as a mediator of chronic fatigue and post-traumatic stress symptoms in middle east respiratory syndrome survivors. Psychiatry Investig. 2019;16:59–64. doi: 10.30773/pi.2018.10.22.3. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354037/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/30605995)\] \[[CrossRef](https://doi.org/10.30773%2Fpi.2018.10.22.3)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Psychiatry+Investig&title=Depression+as+a+mediator+of+chronic+fatigue+and+post-traumatic+stress+symptoms+in+middle+east+respiratory+syndrome+survivors&author=SH+Lee&author=HS+Shin&author=HY+Park&author=JL+Kim&author=JJ+Lee&volume=16&publication_year=2019&pages=59-64&pmid=30605995&doi=10.30773/pi.2018.10.22.3&)\]

18\. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. medRxiv. 2021. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941645/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33688642)\]

19\. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707599/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/19621072)\] \[[CrossRef](https://doi.org/10.1371%2Fjournal.pmed.1000097)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS+Med&title=Preferred+reporting+items+for+systematic+reviews+and+meta-analyses:+The+PRISMA+statement&author=D+Moher&author=A+Liberati&author=J+Tetzlaff&author=DG+Altman&volume=6&publication_year=2009&pages=e1000097&pmid=19621072&doi=10.1371/journal.pmed.1000097&)\]

20\. Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-COV-2 infection: Illness beyond acute infection and public health implications. JAMA. 2020;324:2251–2. doi: 10.1001/jama.2020.22717. \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33206133)\] \[[CrossRef](https://doi.org/10.1001%2Fjama.2020.22717)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=A+proposed+framework+and+timeline+of+the+spectrum+of+disease+due+to+SARS-COV-2+infection:+Illness+beyond+acute+infection+and+public+health+implications&author=SD+Datta&author=A+Talwar&author=JT+Lee&volume=324&publication_year=2020&pages=2251-2&pmid=33206133&doi=10.1001/jama.2020.22717&)\]

21\. Deng W, Guang TW, Yang M, Li JR, Jiang DP, Li CY, et al. Positive results for patients with COVID-19 discharged form hospital in Chongqing, China. BMC Infect Dis. 2020;20:429. doi: 10.1186/s12879-020-05151-y. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303931/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32560694)\] \[[CrossRef](https://doi.org/10.1186%2Fs12879-020-05151-y)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMC+Infect+Dis&title=Positive+results+for+patients+with+COVID-19+discharged+form+hospital+in+Chongqing,+China&author=W+Deng&author=TW+Guang&author=M+Yang&author=JR+Li&author=DP+Jiang&volume=20&publication_year=2020&pages=429&pmid=32560694&doi=10.1186/s12879-020-05151-y&)\]

22\. Liu BM, Yang QQ, Zhao LY, Xie W, Si XY. Epidemiological characteristics of COVID-19 patients in convalescence period. Epidemiol Infect. 2020;148:e108. doi: 10.1017/S0950268820001181. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287303/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32487271)\] \[[CrossRef](https://doi.org/10.1017%2FS0950268820001181)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Epidemiol+Infect&title=Epidemiological+characteristics+of+COVID-19+patients+in+convalescence+period&author=BM+Liu&author=QQ+Yang&author=LY+Zhao&author=W+Xie&author=XY+Si&volume=148&publication_year=2020&pages=e108&pmid=32487271&doi=10.1017/S0950268820001181&)\]

23\. Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. 2020;55:2001217. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236826/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32381497)\]

24\. Osikomaiya B, Erinoso O, Wright KO, Odusola AO, Thomas B, Adeyemi O, et al. ‘Long COVID’: Persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infectious Diseases. 2021;21:304. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993075/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33765941)\]

25\. Peng J, Liu ZY, Yu XJ, Chen XY, Zhang K, Liu Y, et al. Antibody response in COVID-19 patients with and without re-positive RT-PCR results during the convalescent phase. Arch Virol. 2021;166:2299–303. doi: 10.1007/s00705-021-05132-9. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185311/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/34101005)\] \[[CrossRef](https://doi.org/10.1007%2Fs00705-021-05132-9)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Arch+Virol&title=Antibody+response+in+COVID-19+patients+with+and+without+re-positive+RT-PCR+results+during+the+convalescent+phase&author=J+Peng&author=ZY+Liu&author=XJ+Yu&author=XY+Chen&author=K+Zhang&volume=166&publication_year=2021&pages=2299-303&pmid=34101005&doi=10.1007/s00705-021-05132-9&)\]

26\. Xu H, Liu E, Xie J, Smyth RL, Zhou Q, Zhao R, et al. A follow-up study of children infected with SARS-COV-2 from western China. Ann Transl Med. 2020;8:623. doi: 10.21037/atm-20-3192. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290618/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32566560)\] \[[CrossRef](https://doi.org/10.21037%2Fatm-20-3192)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann+Transl+Med&title=A+follow-up+study+of+children+infected+with+SARS-COV-2+from+western+China&author=H+Xu&author=E+Liu&author=J+Xie&author=RL+Smyth&author=Q+Zhou&volume=8&publication_year=2020&pages=623&pmid=32566560&doi=10.21037/atm-20-3192&)\]

27\. Yan N, Wang W, Gao Y, Zhou J, Ye J, Xu Z, et al. Medium term follow-up of 337 patients with coronavirus disease 2019 (COVID-19) in a Fangcang shelter hospital in Wuhan, China. Front Med (Lausanne) 2020;7:373. doi: 10.3389/fmed.2020.00373. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347902/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32719806)\] \[[CrossRef](https://doi.org/10.3389%2Ffmed.2020.00373)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Front+Med+(Lausanne)&title=Medium+term+follow-up+of+337+patients+with+coronavirus+disease+2019+(COVID-19)+in+a+Fangcang+shelter+hospital+in+Wuhan,+China&author=N+Yan&author=W+Wang&author=Y+Gao&author=J+Zhou&author=J+Ye&volume=7&publication_year=2020&pages=373&pmid=32719806&doi=10.3389/fmed.2020.00373&)\]

28\. Zhang S, Liu L, Yang B, Li R, Luo J, Huang J, et al. Clinical characteristics of 134 convalescent patients with COVID-19 in Guizhou, China. Respir Res. 2020;21:314. doi: 10.1186/s12931-020-01580-0. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689638/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33243228)\] \[[CrossRef](https://doi.org/10.1186%2Fs12931-020-01580-0)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Respir+Res&title=Clinical+characteristics+of+134+convalescent+patients+with+COVID-19+in+Guizhou,+China&author=S+Zhang&author=L+Liu&author=B+Yang&author=R+Li&author=J+Luo&volume=21&publication_year=2020&pages=314&pmid=33243228&doi=10.1186/s12931-020-01580-0&)\]

29\. Zheng J, Zhou R, Chen F, Tang G, Wu K, Li F, et al. Incidence, clinical course and risk factor for recurrent PCR positivity in discharged COVID-19 patients in Guangzhou, China: A prospective cohort study. PLoS Negl Trop Dis. 2020;14:e0008648. doi: 10.1371/journal.pntd.0008648. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505432/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32866168)\] \[[CrossRef](https://doi.org/10.1371%2Fjournal.pntd.0008648)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS+Negl+Trop+Dis&title=Incidence,+clinical+course+and+risk+factor+for+recurrent+PCR+positivity+in+discharged+COVID-19+patients+in+Guangzhou,+China:+A+prospective+cohort+study&author=J+Zheng&author=R+Zhou&author=F+Chen&author=G+Tang&author=K+Wu&volume=14&publication_year=2020&pages=e0008648&pmid=32866168&doi=10.1371/journal.pntd.0008648&)\]

30\. Zhou M, Wong CK, Lau YM, Lee JCY, Tam FCC, Lau YM, et al. Cardiovascular sequalae in uncomplicated COVID-19 survivors. PLoS ONE. 2021;16:e0246732. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877588/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33571321)\]

31\. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054–62. doi: 10.1016/S0140-6736(20)30566-3. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270627/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32171076)\] \[[CrossRef](https://doi.org/10.1016%2FS0140-6736(20)30566-3)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Clinical+course+and+risk+factors+for+mortality+of+adult+inpatients+with+COVID-19+in+Wuhan,+China:+A+retrospective+cohort+study&author=F+Zhou&author=T+Yu&author=R+Du&author=G+Fan&author=Y+Liu&volume=395&publication_year=2020&pages=1054-62&pmid=32171076&doi=10.1016/S0140-6736(20)30566-3&)\]

33\. Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463. doi: 10.1016/j.eclinm.2020.100463. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361108/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32838236)\] \[[CrossRef](https://doi.org/10.1016%2Fj.eclinm.2020.100463)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=EClinicalMedicine&title=Follow-up+study+of+the+pulmonary+function+and+related+physiological+characteristics+of+COVID-19+survivors+three+months+after+recovery&author=YM+Zhao&author=YM+Shang&author=WB+Song&author=QQ+Li&author=H+Xie&volume=25&publication_year=2020&pages=100463&pmid=32838236&doi=10.1016/j.eclinm.2020.100463&)\]

34\. Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B, et al. Cardiopulmonary recovery after COVID-19: An observational prospective multicentre trial. Eur Respir J. 2021;57:2003481. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736754/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33303539)\]

35\. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594–600. doi: 10.1016/j.bbi.2020.07.037. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390748/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32738287)\] \[[CrossRef](https://doi.org/10.1016%2Fj.bbi.2020.07.037)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Brain+Behav+Immun&title=Anxiety+and+depression+in+COVID-19+survivors:+Role+of+inflammatory+and+clinical+predictors&author=MG+Mazza&author=R+De+Lorenzo&author=C+Conte&author=S+Poletti&author=B+Vai&volume=89&publication_year=2020&pages=594-600&pmid=32738287&doi=10.1016/j.bbi.2020.07.037&)\]

36\. Liu D, Baumeister RF, Veilleux JC, Chen C, Liu W, Yue Y, et al. Risk factors associated with mental illness in hospital discharged patients infected with COVID-19 in Wuhan, China. Psychiatry Res. 2020;292:113297. doi: 10.1016/j.psychres.2020.113297. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355324/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32707218)\] \[[CrossRef](https://doi.org/10.1016%2Fj.psychres.2020.113297)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Psychiatry+Res&title=Risk+factors+associated+with+mental+illness+in+hospital+discharged+patients+infected+with+COVID-19+in+Wuhan,+China&author=D+Liu&author=RF+Baumeister&author=JC+Veilleux&author=C+Chen&author=W+Liu&volume=292&publication_year=2020&pages=113297&pmid=32707218&doi=10.1016/j.psychres.2020.113297&)\]

37\. Weng J, Li Y, Li J, Shen L, Zhu L, Liang Y, et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. Lancet Gastroenterol Hepatol. 2021;6:344–6. doi: 10.1016/S2468-1253(21)00076-5. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943402/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33711290)\] \[[CrossRef](https://doi.org/10.1016%2FS2468-1253(21)00076-5)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet+Gastroenterol+Hepatol&title=Gastrointestinal+sequelae+90+days+after+discharge+for+COVID-19&author=J+Weng&author=Y+Li&author=J+Li&author=L+Shen&author=L+Zhu&volume=6&publication_year=2021&pages=344-6&pmid=33711290&doi=10.1016/S2468-1253(21)00076-5&)\]

38\. Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: A prospective study. Lancet Respir Med. 2021;9:747–54. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099316/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33964245)\]

39\. Wei J, Yang H, Lei P, Fan B, Qiu Y, Zeng B, et al. Analysis of thin-section ct in patients with coronavirus disease (COVID-19) after hospital discharge. J Xray Sci Technol. 2020;28:383–9. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369060/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32474479)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Xray+Sci+Technol&title=Analysis+of+thin-section+ct+in+patients+with+coronavirus+disease+(COVID-19)+after+hospital+discharge&author=J+Wei&author=H+Yang&author=P+Lei&author=B+Fan&author=Y+Qiu&volume=28&publication_year=2020&pages=383-9&pmid=32474479&)\]

40\. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: A single-centre longitudinal study. Clin Microbiol Infect. 2021;27:89–95. doi: 10.1016/j.cmi.2020.09.023. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510771/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32979574)\] \[[CrossRef](https://doi.org/10.1016%2Fj.cmi.2020.09.023)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Microbiol+Infect&title=Clinical+sequelae+of+COVID-19+survivors+in+Wuhan,+China:+A+single-centre+longitudinal+study&author=Q+Xiong&author=M+Xu&author=J+Li&author=Y+Liu&author=J+Zhang&volume=27&publication_year=2021&pages=89-95&pmid=32979574&doi=10.1016/j.cmi.2020.09.023&)\]

41\. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: A retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–27. doi: 10.1016/S2215-0366(21)00084-5. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023694/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33836148)\] \[[CrossRef](https://doi.org/10.1016%2FS2215-0366(21)00084-5)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet+Psychiatry&title=6-month+neurological+and+psychiatric+outcomes+in+236%E2%80%89379+survivors+of+COVID-19:+A+retrospective+cohort+study+using+electronic+health+records&author=M+Taquet&author=JR+Geddes&author=M+Husain&author=S+Luciano&author=PJ+Harrison&volume=8&publication_year=2021&pages=416-27&pmid=33836148&doi=10.1016/S2215-0366(21)00084-5&)\]

42\. Liang L, Yang B, Jiang N, Fu W, He X, Zhou Y, et al. Three-month follow-up study of survivors of coronavirus disease 2019 after discharge. J Korean Med Sci. 2020;35:e418. doi: 10.3346/jkms.2020.35.e418. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721559/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33289374)\] \[[CrossRef](https://doi.org/10.3346%2Fjkms.2020.35.e418)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Korean+Med+Sci&title=Three-month+follow-up+study+of+survivors+of+coronavirus+disease+2019+after+discharge&author=L+Liang&author=B+Yang&author=N+Jiang&author=W+Fu&author=X+He&volume=35&publication_year=2020&pages=e418&pmid=33289374&doi=10.3346/jkms.2020.35.e418&)\]

43\. Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020;183:16–27.e1. doi: 10.1016/j.cell.2020.08.028. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437501/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32882182)\] \[[CrossRef](https://doi.org/10.1016%2Fj.cell.2020.08.028)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cell&title=Effects+of+COVID-19+on+the+nervous+system&author=C+Iadecola&author=J+Anrather&author=H+Kamel&volume=183&publication_year=2020&pages=16-27.e1&pmid=32882182&doi=10.1016/j.cell.2020.08.028&)\]

44\. van der Sar-van der Brugge S, Talman S, Boonman-de Winter L, de Mol M, Hoefman E, van Etten RW, et al. Pulmonary function and health-related quality of life after COVID-19 pneumonia. Respir Med. 2021;176:106272. doi: 10.1016/j.rmed.2020.106272. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701891/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33302142)\] \[[CrossRef](https://doi.org/10.1016%2Fj.rmed.2020.106272)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Respir+Med&title=Pulmonary+function+and+health-related+quality+of+life+after+COVID-19+pneumonia&author=S+van+der+Sar-van+der+Brugge&author=S+Talman&author=L+Boonman-de+Winter&author=M+de+Mol&author=E+Hoefman&volume=176&publication_year=2021&pages=106272&pmid=33302142&doi=10.1016/j.rmed.2020.106272&)\]

45\. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5:1265–73. doi: 10.1001/jamacardio.2020.3557. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385689/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32730619)\] \[[CrossRef](https://doi.org/10.1001%2Fjamacardio.2020.3557)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA+Cardiol&title=Outcomes+of+cardiovascular+magnetic+resonance+imaging+in+patients+recently+recovered+from+coronavirus+disease+2019+(COVID-19)&author=VO+Puntmann&author=ML+Carerj&author=I+Wieters&author=M+Fahim&author=C+Arendt&volume=5&publication_year=2020&pages=1265-73&pmid=32730619&doi=10.1001/jamacardio.2020.3557&)\]

46\. Ngai JC, Ko FW, Ng SS, To KW, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010;15:543–50. doi: 10.1111/j.1440-1843.2010.01720.x. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192220/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/20337995)\] \[[CrossRef](https://doi.org/10.1111%2Fj.1440-1843.2010.01720.x)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Respirology&title=The+long-term+impact+of+severe+acute+respiratory+syndrome+on+pulmonary+function,+exercise+capacity+and+health+status&author=JC+Ngai&author=FW+Ko&author=SS+Ng&author=KW+To&author=M+Tong&volume=15&publication_year=2010&pages=543-50&pmid=20337995&doi=10.1111/j.1440-1843.2010.01720.x&)\]

47\. Song WJ, Hui CKM, Hull JH, Birring SS, McGarvey L, Mazzone SB, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: Role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med. 2021;9:533–44. doi: 10.1016/S2213-2600(21)00125-9. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041436/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33857435)\] \[[CrossRef](https://doi.org/10.1016%2FS2213-2600(21)00125-9)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet+Respir+Med&title=Confronting+COVID-19-associated+cough+and+the+post-COVID+syndrome:+Role+of+viral+neurotropism,+neuroinflammation,+and+neuroimmune+responses&author=WJ+Song&author=CKM+Hui&author=JH+Hull&author=SS+Birring&author=L+McGarvey&volume=9&publication_year=2021&pages=533-44&pmid=33857435&doi=10.1016/S2213-2600(21)00125-9&)\]

48\. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet. 2003;361:1767–72. doi: 10.1016/S0140-6736(03)13412-5. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112410/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/12781535)\] \[[CrossRef](https://doi.org/10.1016%2FS0140-6736(03)13412-5)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Clinical+progression+and+viral+load+in+a+community+outbreak+of+coronavirus-associated+SARS+pneumonia:+A+prospective+study&author=JS+Peiris&author=CM+Chu&author=VC+Cheng&author=KS+Chan&author=IF+Hung&volume=361&publication_year=2003&pages=1767-72&pmid=12781535&doi=10.1016/S0140-6736(03)13412-5&)\]

49\. Badawi A, Ryoo SG. Prevalence of comorbidities in the middle east respiratory syndrome coronavirus (MERS-COV): A systematic review and meta-analysis. Int J Infect Dis. 2016;49:129–33. doi: 10.1016/j.ijid.2016.06.015. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110556/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/27352628)\] \[[CrossRef](https://doi.org/10.1016%2Fj.ijid.2016.06.015)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int+J+Infect+Dis&title=Prevalence+of+comorbidities+in+the+middle+east+respiratory+syndrome+coronavirus+(MERS-COV):+A+systematic+review+and+meta-analysis&author=A+Badawi&author=SG+Ryoo&volume=49&publication_year=2016&pages=129-33&pmid=27352628&doi=10.1016/j.ijid.2016.06.015&)\]

50\. Daher A, Balfanz P, Cornelissen C, Müller A, Bergs I, Marx N, et al. Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. Respir Med. 2020;174:106197. doi: 10.1016/j.rmed.2020.106197. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573668/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33120193)\] \[[CrossRef](https://doi.org/10.1016%2Fj.rmed.2020.106197)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Respir+Med&title=Follow+up+of+patients+with+severe+coronavirus+disease+2019+(COVID-19):+Pulmonary+and+extrapulmonary+disease+sequelae&author=A+Daher&author=P+Balfanz&author=C+Cornelissen&author=A+M%C3%BCller&author=I+Bergs&volume=174&publication_year=2020&pages=106197&pmid=33120193&doi=10.1016/j.rmed.2020.106197&)\]

51\. Lam MH, Wing YK, Yu MW, Leung CM, Ma RC, Kong AP, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: Long-term follow-up. Arch Intern Med. 2009;169:2142–7. doi: 10.1001/archinternmed.2009.384. \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/20008700)\] \[[CrossRef](https://doi.org/10.1001%2Farchinternmed.2009.384)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Arch+Intern+Med&title=Mental+morbidities+and+chronic+fatigue+in+severe+acute+respiratory+syndrome+survivors:+Long-term+follow-up&author=MH+Lam&author=YK+Wing&author=MW+Yu&author=CM+Leung&author=RC+Ma&volume=169&publication_year=2009&pages=2142-7&pmid=20008700&doi=10.1001/archinternmed.2009.384&)\]

52\. Lee AM, Wong JG, McAlonan GM, Cheung V, Cheung C, Sham PC, et al. Stress and psychological distress among SARS survivors 1 year after the outbreak. Can J Psychiatry. 2007;52:233–40. doi: 10.1177/070674370705200405. \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/17500304)\] \[[CrossRef](https://doi.org/10.1177%2F070674370705200405)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Can+J+Psychiatry&title=Stress+and+psychological+distress+among+SARS+survivors+1+year+after+the+outbreak&author=AM+Lee&author=JG+Wong&author=GM+McAlonan&author=V+Cheung&author=C+Cheung&volume=52&publication_year=2007&pages=233-40&pmid=17500304&doi=10.1177/070674370705200405&)\]

53\. Shi L, Lu ZA, Que JY, Huang XL, Liu L, Ran MS, et al. Prevalence of and risk factors associated with mental health symptoms among the general population in China during the coronavirus disease 2019 pandemic. JAMA Netw Open. 2020;3:e2014053. doi: 10.1001/jamanetworkopen.2020.14053. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330717/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32609353)\] \[[CrossRef](https://doi.org/10.1001%2Fjamanetworkopen.2020.14053)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA+Netw+Open&title=Prevalence+of+and+risk+factors+associated+with+mental+health+symptoms+among+the+general+population+in+China+during+the+coronavirus+disease+2019+pandemic&author=L+Shi&author=ZA+Lu&author=JY+Que&author=XL+Huang&author=L+Liu&volume=3&publication_year=2020&pages=e2014053&pmid=32609353&doi=10.1001/jamanetworkopen.2020.14053&)\]

54\. Wang Y, Shi L, Que J, Lu Q, Liu L, Lu Z, et al. The impact of quarantine on mental health status among general population in China during the COVID-19 pandemic. Mol Psychiatry. 2021;26:4813–22. doi: 10.1038/s41380-021-01019-y. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821451/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33483692)\] \[[CrossRef](https://doi.org/10.1038%2Fs41380-021-01019-y)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol+Psychiatry&title=The+impact+of+quarantine+on+mental+health+status+among+general+population+in+China+during+the+COVID-19+pandemic&author=Y+Wang&author=L+Shi&author=J+Que&author=Q+Lu&author=L+Liu&volume=26&publication_year=2021&pages=4813-22&pmid=33483692&doi=10.1038/s41380-021-01019-y&)\]

55\. Yuan K, Gong YM, Liu L, Sun YK, Tian SS, Wang YJ, et al. Prevalence of posttraumatic stress disorder after infectious disease pandemics in the twenty-first century, including COVID-19: A meta-analysis and systematic review. Mol Psychiatry. 2021;26:4982–98. doi: 10.1038/s41380-021-01036-x. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861006/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33542468)\] \[[CrossRef](https://doi.org/10.1038%2Fs41380-021-01036-x)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol+Psychiatry&title=Prevalence+of+posttraumatic+stress+disorder+after+infectious+disease+pandemics+in+the+twenty-first+century,+including+COVID-19:+A+meta-analysis+and+systematic+review&author=K+Yuan&author=YM+Gong&author=L+Liu&author=YK+Sun&author=SS+Tian&volume=26&publication_year=2021&pages=4982-98&pmid=33542468&doi=10.1038/s41380-021-01036-x&)\]

56\. Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA Psychiatry. 2021;78:682–3. \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33769431)\]

57\. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767–83. doi: 10.1016/S1474-4422(20)30221-0. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332267/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/32622375)\] \[[CrossRef](https://doi.org/10.1016%2FS1474-4422(20)30221-0)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet+Neurol&title=Neurological+associations+of+COVID-19&author=MA+Ellul&author=L+Benjamin&author=B+Singh&author=S+Lant&author=BD+Michael&volume=19&publication_year=2020&pages=767-83&pmid=32622375&doi=10.1016/S1474-4422(20)30221-0&)\]

58\. de Erausquin GA, Snyder H, Carrillo M, Hosseini AA, Brugha TS, Seshadri S. The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning. Alzheimers Dement. 2021;17:1056–65. doi: 10.1002/alz.12255. \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33399270)\] \[[CrossRef](https://doi.org/10.1002%2Falz.12255)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Alzheimers+Dement&title=The+chronic+neuropsychiatric+sequelae+of+COVID-19:+The+need+for+a+prospective+study+of+viral+impact+on+brain+functioning&author=GA+de+Erausquin&author=H+Snyder&author=M+Carrillo&author=AA+Hosseini&author=TS+Brugha&volume=17&publication_year=2021&pages=1056-65&pmid=33399270&doi=10.1002/alz.12255&)\]

59\. Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-COV-2 is associated with changes in brain structure in UK biobank. Nature. 2022;604:697–707. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046077/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/35255491)\]

60\. Rubin R. Collecting data about COVID-19-related brain symptoms. JAMA. 2021;325:712. \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/33620387)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=Collecting+data+about+COVID-19-related+brain+symptoms&author=R+Rubin&volume=325&publication_year=2021&pages=712&pmid=33620389&)\]

61\. Vassalini P, Serra R, Tarsitani L, Koukopoulos A E, Borrazzo C, Alessi F, et al. Depressive symptoms among individuals hospitalized with COVID-19: Three-month follow-up. Brain Sciences. 2021; 11. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471767/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/34573196)\]

62\. Liu L, Ni SY, Yan W, Lu QD, Zhao YM, Xu YY, et al. Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action. EClinicalMedicine. 2021;40:101–11. doi: 10.1016/j.eclinm.2021.101111. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424080/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/34514362)\] \[[CrossRef](https://doi.org/10.1016%2Fj.eclinm.2021.101111)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=EClinicalMedicine&title=Mental+and+neurological+disorders+and+risk+of+COVID-19+susceptibility,+illness+severity+and+mortality:+A+systematic+review,+meta-analysis+and+call+for+action&author=L+Liu&author=SY+Ni&author=W+Yan&author=QD+Lu&author=YM+Zhao&volume=40&publication_year=2021&pages=101-11&doi=10.1016/j.eclinm.2021.101111&)\]

63\. Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: A longitudinal cohort study. Lancet. 2021;398:747–58. doi: 10.1016/S0140-6736(21)01755-4. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389999/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/34454673)\] \[[CrossRef](https://doi.org/10.1016%2FS0140-6736(21)01755-4)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=1-year+outcomes+in+hospital+survivors+with+COVID-19:+A+longitudinal+cohort+study&author=L+Huang&author=Q+Yao&author=X+Gu&author=Q+Wang&author=L+Ren&volume=398&publication_year=2021&pages=747-58&pmid=34454673&doi=10.1016/S0140-6736(21)01755-4&)\]

64\. Laine C, Cotton D. COVID-19: Evaluation and care of patients with persistent symptoms following acute SARS-COV-2 infection. Ann Intern Med. 2021;174:1159–60. doi: 10.7326/M21-2342. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276272/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/34115532)\] \[[CrossRef](https://doi.org/10.7326%2FM21-2342)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann+Intern+Med&title=COVID-19:+Evaluation+and+care+of+patients+with+persistent+symptoms+following+acute+SARS-COV-2+infection&author=C+Laine&author=D+Cotton&volume=174&publication_year=2021&pages=1159-60&pmid=34115532&doi=10.7326/M21-2342&)\]

65\. Matta J, Wiernik E, Robineau O, Carrat F, Touvier M, Severi G, et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med. 2022;182:19–25. doi: 10.1001/jamainternmed.2021.6454. \[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576624/)\] \[[PubMed](https://pubmed.ncbi.nlm.nih.gov/34747982)\] \[[CrossRef](https://doi.org/10.1001%2Fjamainternmed.2021.6454)\] \[[Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA+Intern+Med&title=Association+of+self-reported+COVID-19+infection+and+SARS-CoV-2+serology+test+results+with+persistent+physical+symptoms+among+French+adults+during+the+COVID-19+pandemic&author=J+Matta&author=E+Wiernik&author=O+Robineau&author=F+Carrat&author=M+Touvier&volume=182&publication_year=2022&pages=19-25&pmid=34747982&doi=10.1001/jamainternmed.2021.6454&)\]
